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ABSTRACT
Resistant starch (RS) reaches the large intestine for fermentation and is considered a
prebiotic. We wanted to determine if we could reduce fermentation for future mechanistic studies
and how there is improved insulin sensitivity in human studies with or without increased incretin
hormone glucagon-like peptide 1 (GLP-1). Two main studies were performed.
In the first main study, low potency antibiotics (Ampicillin 1g/L and Neomycin 0.5g/L)
were added to the drinking water of rats to reduce fermentation of RS. Antibiotics were used either
prior (first) to or during (second) feeding of RS. Results demonstrated that low potency antibiotics
given prior to resistant starch feeding were not able to prevent fermentation in the cecum
independently of water or cecal contents gavage (donor rats fed resistant starch). Low potency
antibiotics given during resistant starch feeding were able to reduce fermentation.
The main purpose of second main study was to determine if resistant starch, as either an
isolated starch or in a whole grain flour, increases gene expression of pyruvate carboxylase
(PCase), and glucose-6-phosphatase (G6Pase). These two enzymes are involved in intestinal
gluconeogenesis (IGN) which improves endogenous glucose control. Certain diets can trigger
IGN. Goto-Kakizaki (GK) rats (first) and Sprague Dawley rats (second) were used to measure IGN
gene expression in the fasted or fed state, respectively. GK rats were in four diet groups, two
control diets (highly digestible isolated starch, CON; and low resistant starch whole grain flour,
WG) and two high resistant starch diets (high amount of isolated resistant starch, RS; high amounts
of resistant starch in a whole grain flour, WG+RS). Gene expression was measured in the fasted
state with insulin injection used to model fed state. Sprague Dawley rats were fed the same diets
but with moderate or high fat and gene expression measured in the fed state. High resistant starch
in the diet increased IGN gene expression in the fed state, regardless of fat level. In the fasted state,
viii

there were no significant increases of PCase or G6Pase even with insulin injection. Improvement
of insulin sensitivity regardless of GLP-1 production in humans fed resistant starch may be a result
of IGN.

ix

CHAPTER 1: INTRODUCTION
1.1. Significance of Research
Obesity is considered a key risk factor in the development of hypertension, diabetes,
coronary heart diseases, and colon cancer [1]. Obesity is caused as a consequence of an enriched
fat diet and a sedentary lifestyle. The Centers for Disease Control and Prevention (CDC) stated
that the average fat intake of American people was 33% of energy in 2010. The gut microbiota is
now known as an environmental factor involved in body weight, energy homeostasis, nutrition,
immunomodulation, behavior, and stress response [2, 3]. A high fat diet can lead to dysbiosis,
which is the disruption of the normal balanced state of the gut microbiota [4]. Dysbiosis can lead
to diseases and can be associated with pathogens or can be associated with the change of former
symbionts into pathobionts [5] which release potential toxic products that play an important role
in illnesses such as inflammatory bowel, chronic fatigue syndrome, obesity, cancer, colitis, and
others [6, 7]. The obese microbiome may harvest more energy from the diet without compensation
of increased energy expenditure [8]. Also, in obese people it has been observed that there is a
decrease in phylum Bacteriodetes and an increase in phylum Firmicutes [2]. Cani in 2007,
demonstrated that in mice fed a high fat diet, the variation of gut microbiota is associated with an
increased intestinal permeability and an inflammatory endotoxemia [9]. High saturated fat diets
can induce severe insulin resistance in skeletal muscle [10].
The gut microbiota is the collection of microbial populations that exists in the
gastrointestinal tract including bacteria, archaea, viruses, and some unicellular eukaryotes. In
humans it is estimated that there are 1014 microorganisms, and the colon has up to 1012
microorganisms/ml which is the highest density found in humans. The interaction of the gut
microbiota with the host has influential consequences with metabolism and health. The majority
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of microorganisms found in the colon belong to the phyla Firmicutes, Bacteroidetes,
Actinobacteria, and Protobacteria.
Fermentable fiber is considered a prebiotic that stimulates the growth and/or activity of
bacteria in the colon, and, thus, improve host health [11]. The Dietary Reference Intake (DRI)
committee on fiber set the Adequate Intake (AI) for fiber as 35 g/day for men and 28 g/day for
women. The Agricultural Research Service reported that the mean intake of dietary fiber is 12.113.8 g/day for women and 13.5-17.9 g/day for men. Both levels of intake are lower than
recommended. Fermentable fiber is more bioactive than other non-fermentable fibers because
during its fermentation gases and acids produced result in health benefits. Studies have provided
evidence that resistant starch is a prebiotic, which stimulates the growth of beneficial bacteria in
the colon. Our lab is interested in the fermentation of resistant starch, which is one of the many
types of fermentable fiber.

Its fermentation involves Bacteriodes thetaiotaomicron,

Bifidobacterium spp., and some Lactobacillus spp [12]. Bacteria, mostly in Clostridial clusters use
the products of these bacteria, acetate and lactate, and produce butyrate [13]. Butyrate and other
short chain fatty acids are associated with improved health [14].
It is important to increase the intake of fibers in the daily food consumption. A variety of
fibers is important including consumption of fermentable fibers. Our lab is interested in the
investigation of the benefits of consumption of resistant starch diets in dysbiosis and its role in
obesity and diabetes. It is important to study the effects of resistant starch in rodent models of
obesity and insulin resistance and diabetes as well as the interaction of resistant starch and high fat
diets. In the future, more people can include the consumption of resistant starch in their daily diets
and may improve their health.
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1.2. Objectives
1. Determine if lower potency antibiotics can reduce fermentation for future mechanistic
studies in order to avoid the use of very potent antibiotics such as vancomycin.
2. Determine if a resistant starch diet can improve the insulin sensitivity of Goto-Kakizaki
(GK) rats.
3. Determine if feeding an isolated high resistant starch product or a high resistant starch
whole grain flour would result in increased intestinal gluconeogenesis (IGN) gene
expression in either the fasted or fed state.
4. Determine if a high fat diet affected IGN gene expression compared to a moderate fat
diet.
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CHAPTER 2: LITERATURE REVIEW
2.1. Resistant Starch
The starch properties depend on how organized are amylose and amylopectin molecules
within the granule. Starches were classified by Englyst et al. (1992) by in vitro assay into three
types: (1) rapidly digestible starch digested to glucose in less than 20 minutes, (2) slowly digestible
starch digested between 20 and 120 minutes, and (3) resistant starch [15]. Any starch digested after
120 minutes is considered a resistant starch [16]. Resistant starch resists amylase digestion in the
small intestine and passes directly to the large intestine where it is fermented [17]. Resistant starch
is a non-viscous fiber and it can be classified into four groups depending on source and processing.
Resistant starch 1 is found in whole grains because starch granules are inserted in indigestible plant
matrix. Resistant starch 2 is found in raw potatoes, wheat, high-amylose maize, and others; its
starch granules are native. Resistant starch 3 is any crystallized starch by cooking-cooling. Finally,
resistant starch 4 is starch chemically modified by esterification, cross-linking, or transglycosylation [18]. There is a possible type 5 which is a mixture of starch with lipid moiety[19].
Resistant starch is considered a prebiotic because it is a non-digestible food ingredient that
stimulates the growth and/or activity of certain bacteria in the colon and, thus, benefits host health
[20]. Bacterial fermentation of resistant starch results in production of short chain fatty acids
(SCFAs) mainly as acetate, propionate, and butyrate. Bacteroides thetaiotaomicron,
Bifidobacterium longum, and some Lactobacillus spp attach to the surface of starch molecules and
produce acetate, propionate, succinate, and lactate [21]. Lactate and acetate are used by bacteria
in Clostridium cluster IV and Clostridium cluster XIV to produce butyrate [22, 23]. Acetate,
propionate, and butyrate are involved in energy homeostasis and metabolism. Among the many
functions some examples are: acetate is the most abundant SCFA and it is used for ATP formation,
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propionate is involved in hepatic lipid metabolism, and butyrate is absorbed by the colonic mucosa
and it’s the preferred energy source [24].
Resistant starch has been attributed to promoting several beneficial health effects such as
reduction of colon cancer risk [25], improvement of colon health [26], reduction of diabetes and
reduction of body weight and fat [27], and others. Also, commercial resistant starch is available
and can be used as a food ingredient for lowering the caloric value and improving, textural and
organoleptic characteristics [28]. Therefore, the food industry has developed a special interest to
use resistant starch as a food ingredient to replace rapidly digestible starch.
Our lab uses high amylose maize resistant starch 2 (HAMRS2) which contains ~60%
amylose and ~40% amylopectin [16]. HAMRS2 is used for animal and human studies, and
different results have been observed. Rodent studies demonstrated postprandial glycaemia
reduction [29], increased GLP-1 and PYY peptide [29, 30], increased energy expenditure [27],
reduction of body fat [31], increased pancreatic beta-cell density [32], and others. Human studies
demonstrated that inclusion of resistant starch in the diet can significantly reduce insulin levels
[18], improve peripheral insulin resistance [33], enhance postprandial insulin sensitivity [34],
reduce food intake [35], and others. Americans consume approximately 4.9 grams per day of
resistant starch [36]. However, more research is required in human subjects.
2.2. Gut Microbiota
The human body is populated by several bacteria, archaea, viruses, and unicellular
eukaryotes. Microbiota, microflora, or normal flora is the collection of microorganisms that coexist
peacefully within the host. The human microbiota is estimated to contain 10 14 bacterial cells, and
70% of microbes in the human body live in the colon [37]. Gut microbiota colonization starts at
birth and its composition depends on the way of delivery, vaginal vs. caesarean [38]. The gut
5

microbiota is dominated by two bacterial phyla: Bacteroides and Firmicutes, and in minor
proportions: Proteobacteria, Verrucomicrobia, Actinobacteria, Fusobacteria, and Cyanobacteria
[39]. The gut microbiota is important for the human host because it affects metabolism and immune
functions [40]. Recent research has demonstrated that the gut microbiota plays a key role in
diseases such as colon cancer, obesity, type 2 diabetes, and inflammatory bowel disease [41, 42].
Alterations of the gut microbiota composition are known as dysbiosis. Dysbiosis is the
imbalance of gut microbiota and it is associated with diseases and conditions such as obesity,
diabetes, Crohn’s disease, and ulcerative colitis. The Western diet (rich in fat and sugar) and life
style contribute to the development of dysbiosis [7]. Excess food intake, or the consumption of
wrong types of foods can result in the production of intestinal toxins. The fermentation of these
toxins can increase the growth of pathogens. Also, usage of antibiotics may cause significant
alterations of normal gut microbiota [43]. Dysbiosis leads to gut permeability, causing an increase
in the passage of lipopolysaccharide (LPS), a cell wall component of gram negative bacteria, into
the portal and systemic circulations [44].
The gut microbiota composition is not static because it is greatly affected by the host’s diet
[20]. The gut microbiota of obese subjects is dominated by Firmicutes in greater proportions than
Bacteroidetes; and opposite proportions are found in lean subjects [45]. Resistant starch affects
colonic health, fecal bulk and SCFA metabolism and stimulates probiotic bacteria growth and
activity [28]. Resistant starch is a source of nutrients for colonic bacteria, thus it is considered as
a tool for the modulation of the gut microbiota [46]. Studies in vitro and using animal models had
reported increases in bifidobacteria [47, 48] and Bacteroides [49]. Probiotic bacteria stimulated by
fermentation of resistant starch prevent colonization of the gut and infection by pathogens.
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2.3. Antibiotics
Antibiotics are usually used to treat infections and they are prescribed depending on the
targeted pathogen, Gram positive or Gram negative. The usage of antibiotics could reshape the
microbiota for short or long periods of time [50]. Cani et al. showed that mice fed a high fat diet
that were treated with low potency antibiotics (neomycin and ampicillin) improved glucose
tolerance and cured dysbiosis [51].
2.4. Insulin resistance
Insulin resistance occurs when body cells become resistant to the effect of insulin. In order
to achieve proper effects of insulin, higher levels are demanded. Therefore, the pancreas tries to
compensate by producing more insulin until it is not able to produce enough insulin and the
pancreas suffers damage and type 2 diabetes develops. Insulin resistance is a risk factor for
development of diabetes. High saturated fat diets induce severe insulin resistance. Diets containing
HAMRS2 have demonstrated improvement in insulin resistance in partially diabetic mice [29],
and also increased pancreatic mass [32] in Goto-Kakizaki rats, a lean model of type 2 diabetes.
Also, humans fed diets containing HAMRS2 had demonstrated improvements in insulin sensitivity
[33, 34, 52]. Robertson et al. observed improvement of peripheral but not hepatic insulin resistance
by providing 40 g per day of HAMRS2 for 8 weeks in the diet of men and women with insulin
resistance [33].
Diabetes mellitus is a chronic degenerative metabolic disease characterized by a high
concentration of glucose in blood and insulin cannot clear it. Normal individuals have fasting
glucose in a range of 80 to 100 mg/dl, pre-diabetic individuals have 101 to 125 mg/dl of fasting
glucose, and diabetic individuals have more than 126 mg/dl of fasting glucose. Diabetic subjects
commonly experience excessive thirst, frequent urination, hunger, fatigue, inexplicable weight
gain or loss, and others. Diabetes has reached epidemic proportions due to an increasing sedentary
7

lifestyle, overweight, and obesity [53]. According to the National Institute of Diabetes & Digestive
& Kidney Diseases, 35% of Americans have pre-diabetes and 11.3% of Americans older than 20
years old already have diabetes. Diabetes includes type 1 and type 2. Diabetes type 1 is prevalent
in children and adolescents, but now it is known as insulin independent diabetes. Diabetes type 2
is characterized by inadequate utilization of insulin and it is the most common type of diabetes
diagnosed in obese subjects.
2.5. Intestinal Gluconeogenesis
Glucogenic amino acids, and pyruvate, lactate, propionate, and glycerol are noncarbohydrate carbon substrates utilized for generation of glucose, and this metabolic pathway is
called gluconeogenesis. Gluconeogenesis is necessary for long fasting periods or during intensive
exercise in order to maintain the blood glucose levels necessary for metabolic demands of brain,
muscle and red blood cells. The liver does 90% of the gluconeogenesis and the other 10% is
produced by the kidney.
Nowadays, evidence of intestinal gluconeogenesis (IGN) has been observed. Recent
research demonstrated that IGN has beneficial effects on glucose and energy homeostasis. De
Vadder et al. observed that fermentation products of soluble fiber as propionate and butyrate
activate IGN. IGN leads to signaling from the gut to the brain to reduce hepatic gluconeogenesis
for better glycemic control and insulin sensitivity [54]. The intestine contributes approximately 20
to 25% of total endogenous glucose during fasting periods [55]. Key enzymes that are involved in
IGN

are

glucose-6-phosphatase

(G6Pase),

pyruvate

carboxylase

(PCase),

and

phosphoenolpyruvate carboxykinase cytosolic (PEPCK-C). G6Pase and PEPCK-C gene
expression has been shown in rat and human small intestine [56]. Gene expression of G6Pase and
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PEPCK-C are controlled by insulin in small intestine. IGN could have anti-obesity, antidiabetic
effects, and regulate food intake.
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CHAPTER 3: MICROBIOTA REDUCTION WITH LOW POTENCY ANTIBIOTICS
AND COMPARISON OF RECOVERY WITH PREBIOTIC (RESISTANT STARCH)
AND PROBIOTIC (CECAL TRANSPLANT BY GAVAGE)
3.1. Introduction
The human microbiota is estimated to contain approximately 1014 bacterial cells [45]. The
gastrointestinal tract is the largest organ in the human body and it is rich in molecules considered
nutrients for microorganisms [37]. The large intestine alone contains over 70% of all
microorganisms in the human body [45]. The gut microbiota plays a key role in host health [57],
and it is well recognized as an environmental factor that affects body weight, energy homeostasis,
nutrition, immunodulation, behavior, and stress response [2, 8, 58]. The human gut microbiota is
dominated mainly by phyla Bacteroidetes and Firmicutes, and has minor proportions of
Proteobacteria, Verrucomicrobia, Actinobacteria, Fusobacteria, and Cyanobacteria [39]. Lately,
gut microbiota has been emphasized as a critical organ that plays an essential role in health and
disease [39]. The disturbance of the ecological equilibrium of the gut is known as dysbiosis and it
is linked with pathological processes [59]. Cani et al. demonstrated that the low potency antibiotics
neomycin and ampicillin improved dysbiosis [51] in obese mice. Both are broad-spectrum
antibiotics [60]. Additionally, antibiotics can modulate gut microbiota [61] by producing drastic
short and long term alterations [50, 62].
The gut microbiota is not static and it is greatly affected by composition of the host’s diet.
Resistant starch is a fermentable fiber and is considered a prebiotic [63] because it is a substrate
for specific beneficial endogenous microorganisms and it modifies the composition of the host gut
microbiota [64]. The short chain fatty acids (SCFAs) production is stimulated by fermentation in
large intestine [16]. Fermentation of resistant starch involves the attachment of Bacteroides
thetaiotaomicron (Gram negative), Bifidobacterium longum (Gram positive), and some
Lactobacillus spp (Gram positive) to the surface of starch molecules. Bacteroides spp fermentation
10

products are acetate, propionate and succinate; while products of Bifidobacterium spp and
Lactobacillus spp are lactate and acetate [21]. Lactate and acetate are used by bacteria in
Clostridium cluster IV and Clostridium cluster XIV (Gram positives) to produce butyrate [22, 23].
Rodents have been demonstrated to be good models to study alteration of microbial
communities by administration of antibiotics and interactions between the gut microbiota and the
host [51, 62]. The aim of this research was to determine if low potency antibiotic treatment
(Ampicillin 1g/L and Neomycin 0.5g/L) added to drinking water is able to reduce bacteria and
fermentation of resistant starch by using them either prior to or during feeding of a resistant starch
diet. The overall future purpose of the current research is to be able to do further studies to
determine other beneficial effects of dietary resistant starch besides fermentation and SCFAs
production. The second purpose of this research was to determine if ampicillin and neomycin can
reduce the gut microbiota in order to avoid the use of very potent antibiotics for treatment of
dysbiosis and if resistant starch would be able to promote recovery of the gut microbiota after
antibiotic treatment. In order to accomplish these objectives, we conducted two studies and tested
the effect of antibiotic treatment on the presence of bacteria that ferment resistant starch and use
the products; and measured fermentation markers such as pH, SCFAs, and empty cecum weight.
In Study 1.1, we determined if reduction of the microbiota prior to feeding resistant starch would
subsequently prevent fermentation of resistant starch. Surprisingly rats were able to robustly
ferment resistant starch after the antibiotic treatment. This result led us to the study 1.2, where we
determined if low potency antibiotics would be able to reduce fermentation when resistant starch
is fed at the same time as the antibiotic treatment.
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3.2. Research Design and Methods
Animals and diets
For both studies, protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) at Louisiana State University. Male Sprague Dawley rats were purchased
from Harlan Laboratories Inc. (Indianapolis, IN) at 6 weeks old, maintained in quarantine for 1
week, and fed a standard chow diet. After quarantine, rats were stratified according to their body
weight. Rats were housed individually in wire bottom cages at 21-22°C, 55% humidity, and 12:12
hour light-dark cycle. Rats were fed ad libitum, and had free access to water. During the studies
the body weight, food intake, and food spillage were measured twice a week.
Study 1.1. Twenty nine (n=29) rats were used in this study in two phases (Fig. 3.1.). During
the first phase, the rats were divided into two groups: resistant starch in the diet and no antibiotics
(RS+NAB, n=10) and low dietary resistant starch with antibiotics (NRS+AB, n=19). The rats in
RS+NAB group were fed an AIN-93M based diet (Table 3.1.) with high amylose maize resistant
starch (HAMRS) corn starch diet for 4 weeks. When, they were euthanized the rats were divided
into two subgroups (n=5), one for collecting cecal contents for pooling for a transplant, and the
other subgroup had cecal contents collected individually for bacterial analyses by quantitative realtime polymerase chain reaction (real-time qPCR). Simultaneously, the NRS+AB group was fed
the AIN-93M diet [65], prepared, pelleted, and irradiated before use by Dyets Company
(Bethlehem, PA) and given the antibiotic treatment for 4 weeks (Ampicillin 1g/L and Neomycin
0.5g/L added to their drinking water). This group would have low amylose in the starch in the diet.
The drinking water (before addition of antibiotics) and food cups for this group receiving
antibiotics were autoclaved before use. After week four, five rats from this group were euthanized
to individually collect cecal contents for bacterial analyses by real-time qPCR and the remaining
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14 rats continued into the second phase. In the second phase, after antibiotic treatment, the
remaining 14 rats from the NRS+AB group from phase 1 were divided into two subgroups (n= 7).
The subgroups received either a control water gavage (RS+WtG) or a cecal contents gavage
(RS+CG) from the cecal contents from RS+NAB in phase 1 of the study (RS donor rats),
respectively. The volume for the gavages was 5 ml of 1:10 diluted cecal contents in saline solution.
After the gavage procedure, rats were fed the RS diet used in phase 1 for 3.5 weeks.
2nd PHASE: 3.5 weeks

1st PHASE: 4 weeks

RS+WtG
14 RATS

n=7

ENTER 2ND PHASE

RS: RS in AIN93M
WtG: Water Gavage

NRS+AB (n=19)
NRS: AIN93M no RS
AB: Ampicillin 1g/L +
Neomycin 0.5gL

*5 RATS EUTHANIZED RUN
Real Time qPCR

RS+CG
n=7

N=29

RS: RS in AIN93M

Sprague Dawley rats

CG: Cecal Gavage
(donor)

5 RATS EUTHANIZED CECAL
CONTENTS DONORS
RS+NAB (n=10)
RS: RS in AIN93M

*5 RATS EUTHANIZED RUN
Real Time qPCR

RS+NAB
(POSITIVE CONTROL)

* Targeted bacteria: Lactobacillus spp., Clostridial clusters XIV a & b, Bacteroides spp., Bifidobacterium spp., 16S universal

Figure 3.1. Experimental Design for Study 1.1. Groups included in Phase 1: NRS+AB = AIN93M
no resistant starch diet + antibiotic treatment (Ampicillin 1g/L and Neomycin 0.5g/L added in their
drinking water); and RS + NAB = AIN-93M based diet with high amylose maize resistant starch
(HAMRS) corn starch + no antibiotic treatment. Groups included in Phase 2: RS+NAB = AIN93M based diet with high amylose maize resistant starch (HAMRS) corn starch + no antibiotic
treatment; RS+WtG = HAMRS corn starch + Water gavage; and RS+CG = HAMRS corn starch
diet + Cecal gavage from donors in phase 1. RS+NAB: Group from Phase 1 considered as positive
control for Phase 2 to compare with RS+WtG and RS+CG groups.
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Table 3.1. Diets composition in Study 1.1.
NRS1
RS
Grams
kcal
Grams
kcal
2
Waxy corn starch
620.69
2208.42
61.7
219.55
3,4
High-amylose corn starch
0
619
1733.2
Sucrose
100
387
100
387
5
Casein
140
501.2
135.1
483.66
Cellulose
50
0
0
0
6
Soy bean oil
40
353.6
34.4
304.1
Mineral mix
35
29.4
35
29.4
Vitamin mix
10
38.7
10
38.7
Choline cloride
2.5
0
2.5
0
L-Cystine
1.8
7.2
1.8
7.2
Total
1000
3525.52
1000
3202.81
1
Diets include: NRS= AIN-93M diet [65] and RS = AIN-93M based-with purified high amylose
maize resistant starch (HAMRS) corn starch.
2
AMIOCA® corn starch.
3
HI-MAIZE® resistant corn starch.
4
Waxy corn starch and high-amylose corn starch were gifts from Ingredion Incorporated
(Bridgewater, NJ).
5
Casein was reduced from AIN-93M amount (140 g/kg) for RS diet based on the protein in the
HI-MAIZE® resistant corn starch as analyzed by proximate analysis by Medallion Labs for
Ingredion Incorporated.
6
Soy bean oil was decreased from AIN-93M amount (40 g/kg) for RS diet based on the fat in
the HI-MAIZE® resistant corn starch as analyzed by proximate analysis by Medallion Labs for
Ingredion Incorporated.
Ingredients

Study 1.2. Twenty-four rats were fed ad libitum for 4 weeks and had free access to water.
The diets provided were (1) low fat and HAMRS corn starch (LFRS), (2) high fat and HAMRS
corn starch (HFRS), and (3) low fat and amylopectin control corn starch with no resistant starch
(LFNRS). The compositions of the diets used are listed in Table 3.2. Two groups of rats received
an antibiotic treatment in the drinking water containing Ampicillin 1g/L and Neomycin 0.5g/L
(AB=antibiotic and NAB=no antibiotic). The four groups (n=6) were LFRS+AB, HFRS+AB,
LFNRS+NAB, and LFRS+NAB, where LFNRS+NAB was considered the negative control and
LFRS+NAB was considered the positive control.
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Table 3.2. Diets composition Study 1.2.
LFRS1
HFRS
LFNRS
Grams
kcal
Grams
kcal
Grams
kcal
2
Waxy corn starch
138.35 489.34
0.00
0.00
536.80 1898.66
3,4
High-amylose corn starch
524.00 1467.20
524.66 1469.05
0.00
0.00
Sucrose
100.00 387.00
100.00 387.00
100.00 387.00
5
Casein
132.27 473.53
133.70 478.65
136.00 486.88
Cellulose
18.31
0.00
0.00
0.00
135.00
0.00
6
Soy bean oil
38.87 343.61
93.44 826.01
44.00 388.96
7
Lard
0.00
0.00
100.00 900.00
0.00
0.00
Mineral mix
35.00
29.40
35.00
29.40
35.00
29.40
Vitamin mix
10.00
38.70
10.00
38.70
10.00
38.70
Choline cloride
1.40
0.00
1.40
0.00
1.40
0.00
L-Cystine
1.80
7.20
1.80
7.20
1.80
7.20
Total
1000.00 3235.98
1000.00 4136.00
1000.00 3236.80
1
Diets include: LFRS = low fat and purified high amylose maize resistant starch (HAMRS) corn
starch diet; HFRS = high fat and HAMRS corn starch diet; LFNRS = low fat and amylopectin
control corn starch with no resistant starch.
2
AMIOCA® corn starch.
3
HI-MAIZE® resistant corn starch.
4
Waxy corn starch and high-amylose corn starch were gifts from Ingredion Incorporated
(Bridgewater, NJ).
5
Casein was reduced from AIN-93M amount (140 g/kg) for three diets based on the protein in
the AMIOCA® corn starch and HI-MAIZE® resistant corn starch as analyzed by proximate
analysis by Medallion Labs for Ingredion Incorporated.
6
Soy bean oil was decreased from AIN-93M amount (40 g/kg) for RS diets based on the fat in
the AMIOCA® corn starch and HI-MAIZE® resistant corn starch as analyzed by proximate
analysis by Medallion Labs for Ingredion Incorporated.
7
Lard was added to complete ~40% fat in conjunction with soy bean oil and the fat in the HIMAIZE® resistant corn starch as analyzed by proximate analysis by Medallion Labs for
Ingredion Incorporated for HFRS diet.
Ingredients

Procedures
In studies 1.1 and 1.2, rats were euthanized by cardiac puncture using inhalation of
isoflurane soaked cotton balls as anesthesia in a bell jar. The gastrointestinal tract (GI) was
removed from esophagus to anus, and then it was divided into stomach, small intestine, cecum and
large intestine. The GI parts were weighed full and empty. Fat pads (peritoneal, retroperitoneal,
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and epididymal) were weighed for calculation of total abdominal fat percentage per animal.
Abdominal fat percent was calculated from abdominal cavity fat divided by body weight of the
rats with the GI tract contents removed. Cecal contents were frozen in liquid nitrogen for further
measurements of pH, short chain fatty acids (SCFAs), and targeted bacterial genera that ferment
resistant starch by real-time qPCR. For Study 1.2, blood samples were collected by cardiac
puncture for measurement of GLP-1 active with ELISA kit (ALPCO, NH) and one full cecum per
group was kept for histology of cecum wall.
Cecal contents pH and SCFAs analysis
For studies 1.1 and 1.2, cecal contents were thawed and 0.5 g of each rat’s wet sample was
homogenized in 5 ml of distilled water, for pH measurements. Subsequently, each sample was
acidified with 1 ml of a 25% (w/w) solution of metaphosphoric acid containing 2 g/L 2-ethylbutiryc acid as an internal standard for SCFAs contents. Solids were separated by centrifugation
and filtration. The supernatant was transferred to a GC autosampler vial. Concentrations of SCFAs
were quantitatively determined by gas chromatography by a method described in previous
publication from our laboratory [66].
Bacterial DNA extraction
Study 1.1. After cecal contents were thawed, 500 mg for each rat’s sample were weighed
and placed into a 2 ml Lysing Matrix E tube (MP Biomedicals, OH) containing 1.4 mm ceramic
spheres, 0.1 mm silica spheres, and one 4 mm glass bead; then 825 µl of sodium phosphate, and
275 µl of PLS solution from FastDNA® SPIN kit for Feces (MP Biomedicals, OH) were added.
Immediately, the tubes with cecal contents, Lysing Matrix E, sodium phosphate, and PLS solution
were vortexed for 15 seconds, then centrifuged at 11,400 rpm for 5 minutes and supernatant was
decanted. Next, 978 µl of sodium phosphate buffer and 122 µl of MT buffer were added into the
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tubes and vortexed briefly. Mixture was homogenized using the FastPrep®-24 Instruments (MP
Biomedicals, OH) for 40 seconds at speed setting 6.0 m/s. The lysate was centrifuged at 11,400
rpm for 5 minutes, and DNA was extracted from supernatant by following FastDNA® SPIN kit
for Feces protocol. Purified DNA was quantified using a NanoDrop® Spectrophotometer and
diluted to 1 ng/ µl for storage at -80°C.
Study 1.2. After cecal contents were thawed, approximately 200 mg for each rat’s sample
were weighed and placed into a 2 ml screw-cap tube containing ~ 300 mg of 0.1 mm Zirconia
Silica beads (BioSpec Products Inc, OK), then 100 µl of Lysis buffer prepared with 5 M NaCl, 1
M Tris-HCl (pH 8), 0.5 M EDTA (pH 8), distilled autoclaved water and Lysozyme (Thermo
Scientific, IL) were added. Immediately, the tubes with cecal contents, Zirconia Silica beads, and
Lysis buffer were vortexed and incubated for 30 minutes at 37°C. Next, 1 ml of InhibitEX buffer
from QIAamp® Fast DNA Stool Mini kit (QIAGEN, CA) was added. Next, the mixture was
homogenized two times using a FastPrep®-24 Instrument (MP Biomedicals, OH) for 60 seconds
at speed setting 6.5 m/s. Subsequently, the suspension was heated in a heat-block at 95°C and 250
rpm for 5 minutes, then vortexed for 15 seconds and centrifuged for 3 minutes at 14,000 rpm.
Finally, DNA was extracted from supernatant by following QIAamp® Fast DNA Stool Mini kit
protocol. Purified DNA was quantified using a NanoDrop® Spectrophotometer and diluted to 1
ng/µl for storage at -80°C. The method for DNA extraction was changed for this study due to a
high absorbance at 230 nm wavelength in previous method used in study 1. The method for study
2 resulted in low absorbance at 230 nm wavelength and greater purity for the DNA extract.
Quantitative real-time PCR
In studies 1.1 and 1.2, ABI PRISM 7900 Sequence Detection System, and SDS 2.4
Software (Life Technologies, NY) were used to perform SYBR® Green method of real-time
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qPCR. Targeted bacterial genera, primer sequences, annealing temperature and literature
references are listed in Table 3.3 and 3.4 for studies 1.1 and 1.2, respectively. All reactions were
performed using sterile MicroAmp® Optical 384-well Reaction Plates with Barcode and sealed
with MicroAmp® Optical Adhesive Films (Life Technologies, CA). Each reaction was performed
in triplicates and made of 5µl of 2X SYBR Green Master Mix (Life Technologies, CA), 0.5 µl of
each primer at 10 µM (Integrated DNA Technologies, IA), 0.5 µl of 250 mg/ml bovine serum
albumin (BSA), 0.5 µl of nuclease free water and 3 µl of DNA template in a 10 µl total volume.
Table 3.3. Real-time qPCR primers used to profile cecal contents samples for Study 1.1.
Targeted bacteria

Annealing
Temp (°C)

Primer Sequence

Reference

Firmicutes
Lactobacillus spp
Clostridial cluster IV
Clostridium leptum
subgroup, includes
Faecalibacterium
prausnutzii
Clostridium cluster
XIVa and XIVb
Clostridium coccoides
– Eubacterium rectale
subgroup
Bacteroidetes
Bacteroides group
including Prevotella
and Porphyromonas
Actinobacteria
Bifidobacterium spp

F: TGG ATG CCT TGG CAC TAG GA
R: AAA TCT CCG GAT CAA AGC TTA
CTT AT

55

Haarman &
Knol,
2006[67]

55

Wise &
Siragusa,
2007[68]

55

Matsuki et
al.,
2002[69]

55

Wise &
Siragusa,
2007[68]

55

Bartosch et
al.,
2005[70]

55

Belenguer,
et al.,
2006[71]

F: TTA CTG GGT GTA AAG GG
R: TAG AGT GCT CTT GCG TA

F: AAA TGA CGG TAC CTG ACT AA
R: CTT TGA GTT TCA TTC TTG CGA A
F: GAA GGT CCC CCA CAT TG
R: CAA TCG GAG TTC TTC GTG
F: GGG TGG TAA TGC CGG ATG
R: TAA GCC ATG GAC TTT CAC ACC

Bacterial Domain
16S universal primers

F: GTG STG CAY GGY YGT CGT CA
R: ACG TCR TCC MCN CCT TCC TC
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Table 3.4. Real-time qPCR primers used to profile cecal contents samples for Study 12.
Targeted bacteria

Annealing
Temp
Reference
(°C)

Primer Sequence

Firmicutes
Lactobacillus spp
Clostridium
cluster XIVa and
XIVb
Clostridium
coccoides –
Eubacterium
rectale subgroup
Bacteroidetes
Bacteroides group
including
Prevotella and
Porphyromonas
Actinobacteria
Bifidobacterium
spp
Bacterial
Domain
16S universal
primers

F: TGG ATG CCT TGG CAC TAG GA
R: AAA TCT CCG GAT CAA AGC TTA
CTT AT

60

Haarman &
Knol, 2006[67]

60

Matsuki et al.,
2002[69]

60

Wise &
Siragusa,
2007[68]

F: CTC CTG GAA ACG GGT GG
R: GGT GTT CTT CCC GAT ATC TAC
A

60

Matsuda et al.,
2009[72]

F: GTG STG CAY GGY YGT CGT CA
R: ACG TCR TCC MCN CCT TCC TC

60

Belenguer, et
al., 2006[71]

F: AAA TGA CGG TAC CTG ACT AA
R: CTT TGA GTT TCA TTC TTG CGA
A
F: GAA GGT CCC CCA CAT TG
R: CAA TCG GAG TTC TTC GTG

The primers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and
their specificity checked with the GenBank database by blast search of primers sequences in
National Center for Biotechnology Information website (http://www.ncbi.nlm.nih.gov) on
September 30, 2015. The cycling conditions were one cycle of 95°C for 10 minutes, then 40 cycles
of 95°C for 15 seconds, primer-specific annealing temperature (Table 3.2.) for 1 minute, 72°C for
40 seconds, and one cycle of 72°C for 30 seconds. After amplification, a dissociation step of 95°C
for 15 seconds, 60°C for 15 seconds, and 95°C for 15 seconds, was included. The results were
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expressed as Ct values for targeted bacterial genera, where higher Ct equals lower apparent starting
amounts of a bacterial genera DNA. For study 1.1, we stopped at the use of Ct only for analysis
because we observed that feeding resistant starch subsequent to antibiotic treatment resulted in the
same Ct values as rats fed resistant starch that were never treated with antibiotics. We viewed this
as a pilot study for study 1.2.
Study 1.2. Several bacteria strains representing targeted genera were cultured in specific
broths (conditions described in Table 3.5). Serial dilutions (1:10) starting with one milliliter of the
cultured bacteria plus 9 milliliters of PBS were made. These dilutions of bacteria were spread on
agar plates using 100 µl. Colony Forming Units (CFU) were determined for the serial dilutions
and converted to log CFU. The specific bacteria cultured were: Lactobacillus plantarum strain
ATCC 4163 (Lactobacillus genera), Clostridium coccoides strain ATCC 29236 (Clostridial
cluster XIVa and b, which includes Clostridium coccoide, Eubacterium rectale subgroup,
Lachnospiraceae, and Ruminococcus), Bacteroides fragilis strain ATCC 23745 (Bacteroides
group, including Prevotella and Porphyromonas genera), Bifidobacterium longum strain ATCC
15708 (Bifidobacteria genera), and Escherichia coli strain ATCC 25922 (total bacteria using 16S
universal primers). DNA was extracted from 1 ml of undiluted broth culture by the method
described above for study 1.2, and dilutions of DNA (serial 1:4 dilutions) were interpolated with
dilutions for log CFU. Standard curves were constructed as Ct versus log CFU (Table 3.6). The
primers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and their
specificity checked as described above in study 1.1. The cycling conditions were one cycle of 95°C
for 10 minutes, then 40 cycles of 95°C for 15 seconds, primer-specific annealing temperature
(Table 3.4.) for 1 minute, 78°C for 40 seconds, and after amplification a dissociation step was
included as mentioned above. Treatment replicate log CFUs for each targeted bacteria were
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determined using the equations for the lines obtained from standard curves.
Table 3.5. Culture conditions Study 1.2.
Bacteria strains

Incubation
Temp (°C)

Time
(hours)

30

48

37

72-96

Brewer Modified Thioglycollate medium
(BD Diagnostic Systems, MD)1

37

72-96

Brewer Modified Thioglycollate medium
(BD Diagnostic Systems, MD)1

37

72-96

Media

Firmicutes
Lactobacillus plantarum
Clostridium coccoides
Bacteroidetes
Bacteroides fragilis

de Man-Rogosa-Sharpe Agar (Difco
Laboratories, MI)1
reinforced Clostridial agar (Oxoid, UK) 1

Actinobacteria
Bifidobacterium longum

Bacterial Domain
16S universal
Luria Broth (Difco Laboratories, MI)2
Escherichia coli
37
24
1
Grown in aerobic conditions.
2
Grown in a chemically generated anaerobic system using an anaerobis box GasPak™ EZ
(Mitsubishi Gas Chemical America Inc., NY).

Table 3.6. Standard curves Study 2.
Bacteria strains
Firmicutes
Lactobacillus
plantarum
Clostridium
coccoides
Bacteroidetes
Bacteroides
fragilis
Actinobacteria
Bifidobacterium
longum
Bacterial Domain
16S universal
Escherichia coli

R2

Efficiency
(%)

-3.557

0.999

91.00

log CFU= -0.2395*(Ct)+12.102

-3.38

0.996

97.50

log CFU= -0.2881*(Ct)+11.785

-3.38

0.990

97.60

log CFU= -0.2215*(Ct)+9.3945

-3.553

0.996

91.20

log CFU= -0.2897*(Ct)+13.815

-3.45

0.999

95.00

Equation

Slope

log CFU= -0.2947*(Ct)+14.694
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Resistant Starch Assay
For study 1.2, 100±5 mg of thawed cecal contents were weighed for each rat sample.
Resistant starch was measured following the protocol of the Resistant Starch Assay Kit
(Megazyme Inc, IL).
Histology of cecum wall
For study 1.2., one cecum per group was not used for cecal contents analysis and was
placed with contents into a jar with 100 ml of 10% formalin for 72 hours until each one acquired
a firm texture. Next, approximately one third of each hardened cecum was cut off from the bottom
away from the two openings (small intestine or rest of large intestine) and placed into histology
cassettes. The histologist carefully removed the contents and cut cross-sectional slices so that the
wall of the cecum could be visualized with Hematoxylin and Eosin stain. Pictures of slides were
made by the Cell Biology & Bioimaging Core at Pennington Biomedical Research Center using a
NanoZoomer-SQ Digital slide scanner (Hamamatsu, Japan) at 20X magnification. Images from
tissue samples were analyzed using NanoZoomer Digital PathologyView2 Software. The heights
of mucosal, submucosal, and muscularis layers were measured in three different locations per slide
image and then averaged.
Statistical Analysis
Statistical differences were analyzed in the Statistical Analysis Software SAS® version
9.3. A one-way ANOVA analysis was executed and followed by F-protected least significant
difference (LSD) post-hoc mean comparison tests using the MIXED procedure. In order to test
equal variance, normal distribution, and to identify outliers an UNIVARIATE procedure was
performed in the MIXED procedure. If normality assumption was not met, data were transformed
to log10. A p value of < 0.05 was considered statistically significant. In Study 1.1, one outlier was
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detected for Clostridium Cluster XIV (NRS+AB: 21.34) in phase 1, and in phase 2 Clostridium
Cluster IV data was log 10 transformed for statistical analyses. In Study 1.2, two outliers were
detected in GLP-1 active data (LFRS+AB: 2.99; LFRS+AB: 0.63), and propionate data were
transformed to log 10 for statistical analyses. Data were presented in their original form and
expressed as means ± standard error.
3.3. Results
Study 1.1.
Cecal contents pH, ECW, SCFAs, and ABF%
In phase 1 (Table 3.7.), as expected, the group fed resistant starch (RS+NAB) demonstrated
greater fermentation than the group that received antibiotic treatment and no dietary resistant starch
(NRS+AB); through lower pH of cecal contents (p<0.0002), higher production of propionate
(p<0.0166), and lower abdominal fat percent (ABF %) (p<0.0213). Also, production of acetate
and butyrate were not detectable in NRS+AB group. However, empty cecum weights (ECW) were
not significantly different (p=0.0652) from one another.
In phase 2 (Table 3.7.), rats in the RS+NAB group from phase 1 were considered a positive
control to compare with rats in the RS+WtG and RS+CG groups for pH and SCFAs production,
but not for ECW or ABF% because rats in the RS+NAB group were younger (11 weeks old) than
rats in RS+WtG and RS+CG groups (14.5 weeks old) at euthanasia. The positive control group
pH was significantly lower than RS+WtG (p<0.0067) or RS+CG (p<0.0439) groups. However,
RS+WtG and RS+CG groups produced acetate and butyrate to the same extent as the positive
control group. Only propionate production of RS+CG group was significantly lower than the
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positive control (p<0.0276) but not significantly different from RS+WtG (p=0.0817) group.
Additionally, ECW and ABF% were not significantly different between RS+WtG and RS+CG.
Table 3.7. Cecal contents pH, ECW, SCFAs, and ABF% for study 1.11.
Phase 12

Variables

Phase 23

pH

NRS+AB
RS+NAB
8.44±0.02a 6.17±0.18b

RS+NAB4 RS+WtG
6.17±0.19b 6.94±0.16a

RS+CG
6.71±0.16a

ECW5 (g)

0.67±0.11a 0.93±0.07a

-

1.30±0.15a

Acetate (mmol)
Propionate (mmol)
Butyrate (mmol)

6

UND
8.61±1.35
0.39±0.04b 1.66±0.32a
UND 1.99±0.43

1.33±0.15a

8.61±1.35a 9.35±1.66a 7.86±1.56a
1.66±0.32a 1.10±0.19ab 0.93±0.19b
1.99±0.43a 3.24±0.54a 2.61±0.54a

ABF%7
1.88±0.14a 1.43±0.10b
1.79±0.10a 1.78±0.10a
1
Data are presented in their original form and expressed as means ± standard error. P value< 0.05
was considered statistically significant and it is represented with different letters horizontally.
2
Groups include in Phase 1: NRS+AB = AIN93M no resistant starch diet + antibiotic treatment
(Ampicillin 1g/L and Neomycin 0.5g/L diluted in their drinking water); and RS + NAB = AIN93M diet based high amylose maize resistant starch (HAMRS) corn starch + no antibiotic
treatment.
3
Groups include in Phase 2: RS+NAB = AIN-93M diet based high amylose maize resistant starch
(HAMRS) corn starch + no antibiotic treatment; RS+WtG = HAMRS corn starch diet + Water
gavage; and RS+CG = HAMRS corn starch diet + Cecal gavage from donors in phase 1.
4
RS+NAB: Group from Phase 1 consider as positive control for Phase 2 to compare with
RS+WtG and RS+CG groups for pH, acetate, propionate, and butyrate.
5
ECW = Empty cecum weight.
6
7

UND = undetectable.
ABF% = Abdominal fat percent.

DNA amplification of the targeted bacteria in phase 1 and phase 2
In phase 1 (Fig. 3.2), the starting amounts of total bacteria appeared to be similar as
amplified DNA extracts reached the threshold at similar cycles using 16S universal primers for
the RS+NAB group and NRS+AB group (p= 0.1118, RS+NAB’s Ct = NRS+AB’s Ct). However,
RS+NAB group appeared to have greater starting amounts of Bididobacterium spp (p<0.0001),
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Clostridium cluster XIVa and b (p< 0.0001), and Lactobacillus (p<0.0007) than NRS+AB
(RS+NAB’s Ct < NRS+AB’s Ct). Of the targeted genera, only Bacteroides for NRS+AB group
had apparently greater starting amounts (as their amplified DNA extracts reached the threshold at
a significantly lower cycle) than the RS+NAB group (p<0.012) (NRS+AB’s Ct < RS+NAB’s Ct).
This result concurs with the result of propionate being the only SCFA produced for NRS+AB
group, and propionate being one of the major fermentation products of Bacteroides spp.

16S universal

Bifidobacterium spp

*

*

Bacteroides
Clostridium cluster XIVa and XIVb

*

Lactobacillus spp

*
0

5

10

15

20

25

30

35

40

Ct
RS+NAB

NRS+AB

Figure 3.2. Cycles to threshold (Ct) for targeted bacteria in phase 1 of Study 1.1. Higher Ct means
slower amplification. Asterisk (*) next to bars indicates a statistically significant difference (p<
0.05). Data are presented in their original form and expressed as means ± standard error. Groups
included in phase 1: AB+NRS = Amylopectin control corn starch with no resistant starch and
antibiotic treatment (Ampicillin 1g/L and Neomycin 0.5g/L added in their drinking water); and
RS+NAB = purified high amylose maize resistant starch (HAMRS) corn starch diet and no
antibiotic treatment.
In phase 2 (Fig 3.3), there were no differences in the apparent starting amounts of DNA for
total bacteria with 16S universal primers (p=0.3632), Bifidobacterium spp (p=0.6529), Clostridium
cluster XIVa and b (p=0.3329), and Lactobacillus spp (p=0.3887) between the positive control
group (RS+NAB), RS+WtG, and RS+CG (RS+NAB’s Ct = RS+WtG’s Ct= RS+CG’s Ct). The
positive control group had a significantly greater apparent starting amount for Bacteroides spp
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than RS+CG group (p<0.0312) and RS+WtG (p<0.0364) (RS+NAB’s Ct < RS+WtG’s Ct;
RS+NAB’s Ct < RS+CG’s Ct). However, the apparent starting amount of Bacteroides spp for
RS+CG group and RS+WtG group (p=0.9322) were not significantly different (RS+WtG’s Ct=
RS+CG’s Ct). These results demonstrated that regardless of the type of gavage (water or cecal
contents from donor rats), the apparent amounts of all but one of the targeted genera of bacteria
were the same. Also the groups with prior antibiotic treatment had reduced apparent amounts of
Bacteroides spp compared to the positive control group never treated with antibiotics. This was a
reversal from antibiotic treatment.

16S universal
Bifidobacterium spp
Bacteroides

*

Clostridium cluster XIVa and XIVb
Lactobacillus spp
0
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RS+CG

RS+WtG

RS+NAB

Figure 3.3. Cycles to threshold (Ct) for targeted bacteria in phase 2 of Study 1.1. Higher Ct means
slower amplification. Asterisk (*) next to bars indicates a statistically significant difference (p<
0.05). Data are presented in their original form and expressed as means ± standard error. Groups
included in Phase 2: RS+NAB = no antibiotic treatment + purified HAMRS corn starch diet;
RS+WtG = HAMRS corn starch diet and water gavage; and RS+CG = Cecal gavage from donors
fed resistant starch in phase 1 in HAMRS corn starch diet .
Study 1.2.
Cecal contents pH, ECW, SCFAs, and ABF%
Results (Table 3.8.) demonstrated that antibiotic treatment at the same time as feeding
resistant starch was able to diminish the ability of the rats to ferment resistant starch. The
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LFNRS+NAB group (negative control) did not have a significantly different pH of cecal contents
compared to groups fed resistant starch and concurrently treated with antibiotics (LFRS+AB,
p=0.3448 and HFRS+AB, p=0.9903). As also stated above in phase 1 in study 1.1, ECW was also
not a reliable indicator of fermentation when rats are given antibiotic treatment. ECW of groups
given antibiotic treatment, LFRS+AB (p<0.0001) and HFRS+AB (p<0.0005), were significantly
greater than the negative control group (LFNRS+NAB); and ECW of LFRS+AB (p=0.1940) was
not significantly different from the positive control group (LFRS+NAB) or from the HFRS+AB
group (p=0.1632). However, the ECW for the HFRS+AB group was significantly lower than the
positive control group (p<0.0124).
Acetate and butyrate short-chain fatty acid production was also reduced with antibiotic
treatment (Table 3.8.). Acetate production for the LFRS+AB group was significantly lower than
the positive control (p<0.0140), significantly greater than the negative control (p<0.0163), and not
different from the HFRS+AB group (p=0.9639). Similar differences were observed for butyrate
production except that the two groups treated with antibiotics had lower amounts than the negative
control group (Table 3.8.). Thus, there was some increased production of acetate with the
combination of resistant starch and antibiotics with both low and high fat diets, but the antibiotics
reduced production compared to the positive control. Propionate production was similar for the
two groups with low fat diets with resistant starch regardless of antibiotic treatment. The high fat
diet with antibiotic treatment and resistant starch had less propionate production than the low fat
group with antibiotic treatment and resistant starch, but had similar production as the positive
control group.
The abdominal fat percent (Table 3.8.) was different according to dietary fat levels with
the group with a high fat diet having the greatest ABF %. ABF % was significantly greater for the
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HFRS+AB group compared to the LFRS+AB (p<0.045), and negative control group (p<0.0263)
or positive control group (p<0.0169).
Table 3.8. Cecal contents pH, ECW, SCFAs, and ABF% for study 1.21.
Variables
LFRS+AB2
HFRS+AB
LFNRS+NAB3
LFRS+NAB4
pH
8.23±0.06a
8.39±0.07a
8.39±0.10a
6.05±0.18b
5
ECW (g)
1.27±0.07ab
1.08±0.07b
0.51±0.04c
1.45±0.15a
Acetate (mmol)
0.151±0.024b 0.149±0.035bc
0.060±0.007c
0.469±0.080a
Propionate (mmol)
0.096±0.004a
0.074±0.006b
0.013±0.018c 0.087±0.023ab
Butyrate (mmol)
0.004±0.001c
0.004±0.002c
0.013±0.021b
0.074±0.007a
6
ABF%
1.46±0.14b
1.81±0.05a
1.41±0.13b
1.38±0.12b
1
Data are presented in their original form and expressed as means ± standard error. P value<
0.05 was considered statistically significant and it is represented with different letters
horizontally.
2
Groups include: LFRS+AB = low fat, purified high amylose maize resistant starch (HAMRS)
corn starch diet, antibiotic treatment (Ampicillin 1g/L and Neomycin 0.5g/L added in their
drinking water); HFRS+AB = high fat, HAMRS corn starch diet, antibiotic treatment;
LFNRS+NAB = low fat, AIN-93M no resistant starch diet, no antibiotic treatment; and
LFRS+NAB = low fat, HAMRS corn starch diet, no antibiotic treatment.
3
LFNRS+NAB = negative control.
4
LFRS+NAB = positive control.
5
ECW = Empty cecum weight.
6
ABF% = Abdominal fat percent.

Targeted bacteria
The results for standard curves of bacteria are listed in table 3.9. For Bacteroides spp,
Bifidobacterium spp, and Clostridium cluster XIVa and b bacteria not all standard dilutions fell
within the acceptable range for amplification of 90 (slope = -3.6) to 110% (slope = -3.0). However,
some treatment replicates for rats treated with antibiotics for some genera fell below the lowest
acceptable standard; and some treatment replicates from rats not treated with antibiotics fell above
the highest acceptable standard. This was in line with our hypotheses for this study. To address
this, the equations for the two lines, acceptable slope and inclusion of a standard that when included
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gave a line with an efficiency below 90% (~80%), were used to determine the treatment replicate
log CFU. The results for the samples were less than 1% different for the two equations and were
considered acceptable for statistical analysis. Other options were deemed either technically not
possible or not feasible. For example, greater dilutions of some treatment replicates from rats not
treated with antibiotics resulted in too low amounts of DNA to promote amplification; and for
extraction of some treatment replicates for rats treated with antibiotics much greater amounts of
precious cecal contents would be required.
Table 3.9. Standard curves for study 1.2.

Bacteria strains
Firmicutes
Lactobacillus
plantarum
Clostridium
coccoides
Bacteroidetes
Bacteroides
fragilis
Actinobacteria
Bifidobacterium
longum
Bacterial Domain
16S universal

R2

Efficiency
(%)

-3.557

0.999

91.00

-3.38

0.996

97.50

log CFU= 0.2881*(Ct)+11.785

-3.38

0.990

97.60

log CFU= 0.2215*(Ct)+9.3945

-3.553

0.996

91.20

log CFU= 0.2897*(Ct)+13.815

-3.45

Equation

Slope

log CFU= 0.2947*(Ct)+14.694
log CFU= 0.2395*(Ct)+12.102

0.999

95.00

Escherichia coli

Primers for Lactobacillus spp. and Clostridium cluster XIVa and b were initially designed
for use with a Taqman® probe [67, 69], but the specificity of the probe did not allow for detection
of amplification. Therefore, we successfully changed to use of the primers with SYBR green. The
primers for Lactobacillus spp. resulted in 89% specificity and Clostridium cluster XIVa and b
resulted in 60% specificity excluding chloroplasts and clones. Primers initially used for
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Bifidobacterium spp.[70], exhibited two peaks in the melting curve at ~80oC that appeared to not
be primer dimers based on the high temperature for melting. We changed to the primers from
Matsuda et al[72]. Primers for Bacteroides spp. and Bifidobacterium spp. had 57% and 75%,
specificity, respectively.
The results for targeted bacteria expressed in log CFU are shown in Table 3.10. The
negative control group (LNRS+NAB) had the greatest log CFU of Lactobacillus spp. compared to
LFRS+AB group (p<0.0333) or HFRS+AB group (p<0.0334). However, the negative control
group was not significantly different from the positive control group (LFRS+NAB, p=0.1453).
Also, the positive control group was not significantly different from LFRS+AB group (p=0.3512)
or HFRS+AB group (p=0.2206). The log CFU of Clostridium cluster XIVa and b were not
significantly different among the four groups. The negative control group had the lowest log CFU
of Bacteroides spp. compared to the positive control group (p<0.0114), LFRS+AB group
(p<0.0008) or HFRS+AB group (p<0.0463). However, the positive control group had similar log
CFU of Bacteroides spp. as LFRS+AB group (p=0.2285) or HFRS+AB group (p=0.4949). The
positive and negative control groups had similar (p=0.9416) log CFU of Bifidobacterium spp. and
they both had greater log CFU compared to LFRS+AB group (LFRS+NAB, p=0.0056;
LFNRS+NAB, p<0.0065) or HFRS+AB group (LFRS+NAB, p<0.0426; LFNRS+NAB,
p<0.0487). Additionally, the LFRS+AB and the HFRS+AB groups had similar (p=0.4180) log
CFU of Bifidobacterium spp. Finally, the 16S universal bacteria domain log CFU for the
LFRS+AB group was greater than log CFU of the HFRS+AB group (p<0.0286) or the negative
control group (p<0.0018), but not significantly different from the positive control group
(p=0.0528). The negative control group had the lowest log CFU of 16S universal bacteria domain
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compared to the LFRS+AB group, however it was not significantly different from the positive
control group (p=0.1169) or the HFRS+AB group (p=0.1977).
Table 3.10. Bacteria genera in log CFU for study 1.2.
Bacterial Populations2
(log CFU)

LFRS+AB

HFRS+AB

LFNRS+NAB3

LFRS+NAB4

Lactobacillus spp.
5.48±0.40b
5.20±0.49b
6.75±0.07a
6.04±0.39ab
Clostridium XIVa and b
6.36±0.34a
5.91±0.55a
6.74±0.12a
6.66±0.43a
Bacteroides spp.
5.00±0.23a
3.74±0.59a
2.35±0.56b
4.19±0.32a
Bifidobacterium spp.
2.62±0.27b
3.27±0.97b
4.95±0.54a
5.01±0.49a
16S universal
9.27±0.11a
8.83±0.14b
8.58±0.12b
8.88±0.14ab
1
Data are presented in their original form and expressed as means ± standard error. P value<
0.05 was considered statistically significant and it is represented with different letters
horizontally.
2
Groups include: LFRS+AB = low fat, purified high amylose maize resistant starch (HAMRS)
corn starch diet, and antibiotic treatment (Ampicillin 1g/L and Neomycin 0.5g/L added in their
drinking water); HFRS+AB = high fat, HAMRS corn starch diet, and antibiotic treatment;
LFNRS+NAB = low fat, amylopectin control corn starch with no resistant starch, and no
antibiotic treatment; and LFRS+NAB = low fat, HAMRS corn starch diet, and no antibiotic
treatment.
3
LFNRS+NAB: Negative control group
4
LFRS+NAB: Positive control group

GLP-1 active secretion in plasma
Previous research demonstrated that feeding resistant starch stimulates GLP-1 active
secretion [30, 31]. GLP-1 active (Fig. 3.4.) measured in plasma in groups given antibiotic
treatment, LFRS+AB (p<0.0121) and HFRS+AB (p<0.0076), was greater than the positive control
group (LFRS+NAB). The negative control group was different from the other three groups
(HFRS+AB, p<0.0001; LFRS+AB, p<0.0001; LFRS+NAB, p<0.0152).
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2.00

1.80

a

a

GLP-1 Active (pM)

1.60
1.40
1.20

b

1.00
0.80
0.60

c

0.40
0.20

0.00
LFRS+AB

HFRS+AB

LFNRS+NAB

LFRS+NAB

Figure 3.4. GLP-1 active for Study 1.2. Groups include: LFRS+AB = low fat, purified high
amylose maize resistant starch (HAMRS) corn starch diet, and antibiotic treatment (Ampicillin
1g/L and Neomycin 0.5g/L added in their drinking water); HFRS+AB = high fat, HAMRS corn
starch diet, and antibiotic treatment; LFNRS+NAB = low fat, amylopectin control corn starch with
no resistant starch., and no antibiotic treatment; and LFRS+NAB = low fat, HAMRS corn starch
diet, and no antibiotic treatment. Data are presented in their original form and expressed as means
± standard error. Different letters above columns indicate a statistically significant difference.
Resistant starch assay results
Results shown in Figure 3.5 demonstrated that antibiotic treatment completely eliminated
the ability to ferment resistant starch in the cecum. Groups given antibiotic treatment, LFRS+AB
(p<0.0001) and HFRS+AB (p<0.0001), had greater resistant starch in cecal contents than the
positive control group (LFRS+NAB), which was about double the amount. This demonstrated that
at the mechanistic, proof-of-concept dietary levels of resistant starch used in this study and
previous studies about half of the resistant starch is not fermented. Resistant starch in cecal
contents for groups given antibiotic treatment, LFRS+AB and HFRS+AB, were not significantly
different from one another (p<0.6897). These results demonstrated that antibiotic treatment
eliminated the ability to ferment resistant starch in the cecum of rats in both low and high fat diets.
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25.00

Resistant Starch (g/100g)

20.00

a

a

15.00

b
10.00

5.00

c

0.00
LFRS+AB

HFRS+AB

LFNRS+NAB

LFRS+NAB

Figure 3.5. Resistant starch (g/100g) for Study 1.2. Groups include: LFRS+AB = low fat, purified
high amylose maize resistant starch (HAMRS) corn starch diet, and antibiotic treatment
(Ampicillin 1g/L and Neomycin 0.5g/L added in their drinking water); HFRS+AB = high fat,
HAMRS corn starch diet, and antibiotic treatment; LFNRS+NAB = low fat, amylopectin control
corn starch with no resistant starch., and no antibiotic treatment; and LFRS+NAB = low fat,
HAMRS corn starch diet, and no antibiotic treatment. Data are presented in their original form and
expressed as means ± standard error. Different letters above columns indicate a statistically
significant difference.
Histology
In phase 1 of study 1.1 the ECW were not different, so one rat from each group was used
in study 1.2 for histological examination of the cecal wall (Fig 3.6 and Table 3.10.). The cecal
walls of the positive control (LFRS+NAB) and the two groups treated with antibiotics (HFRS+AB
and LFRS+AB) were numerically greater than the cecal wall of the negative control
(LFNRS+NAB). This gives some indication of why rats treated with antibiotics have increased
weights for empty cecum weights.
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A. LFRS+AB

B. HFRS+AB

M
SM

M

SM
Mus
Mus

C. LFNRS+NAB

D. LFRS+NAB

M

Mus
SM

SM

M

Mus

Figure 3.6. Histology of cecum wall at magnification 20X. Layers: mucosal (M), submucosal
(SM), and muscularis (Mus). A. LFRS+AB = low fat, purified high amylose maize resistant starch
(HAMRS) corn starch diet, and antibiotic treatment (Ampicillin 1g/L and Neomycin 0.5g/L added
in their drinking water). B. HFRS+AB = high fat, HAMRS corn starch diet, and antibiotic
treatment. C. LFNRS+NAB = low fat, amylopectin control corn starch with no resistant starch and
no antibiotic treatment. D. LFRS+NAB = low fat, HAMRS corn starch diet, and no antibiotic
treatment.
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Table 3.10. Cecal wall measurements of mucosa, submucosa and muscularis layers for study 1.2.
Groups
LFRS+AB1 HFRS+AB LFNRS+NAB2 LFRS+NAB3
Mucosa (µm)
171.741
192.381
180.430
180.630
Submucosa (µm)
20.031
42.808
26.015
63.491
Muscularis (µm)
95.283
91.668
58.593
76.069
Total (µm)
287.055
326.857
265.038
320.191
1
Groups include: LFRS+AB = low fat, purified high amylose maize resistant starch (HAMRS)
corn starch diet, and antibiotic treatment (Ampicillin 1g/L and Neomycin 0.5g/L diluted in their
drinking water); HFRS+AB = high fat, HAMRS corn starch diet, and antibiotic treatment;
LFNRS+NAB = low fat, amylopectin control corn starch with no resistant starch., and no
antibiotic treatment; and LFRS+NAB = low fat, HAMRS corn starch diet, and no antibiotic
treatment.
2
LFNRS+NAB: Negative control group
3
LFRS+NAB: Positive control group
3.4. Discussion
The results observed in this research demonstrated that antibiotic treatment with low
potency antibiotics added to drinking water prior to resistant starch feeding was able to reduce
bacteria, but not able to prevent subsequent fermentation of resistant starch. However, antibiotic
treatment given during resistant starch feeding was able to completely reduce 100% of the
fermentation of resistant starch as demonstrated by the resistant starch assay for groups given the
antibiotic treatment (LFRS+AB and HFRS+AB). Previously we estimated, based on the
metabolizable energy value for the HAMRS product, that the mechanistic, proof-of-concept
amount of resistant starch used in our studies was 50% fermented. This was confirmed in study
1.2 as the antibiotic treatment resulted in ~two times the amount of cecal contents resistant starch.
The reduction of fermentation was also reflected by cecal contents pH as groups treated with
antibiotics had greater pH values than the positive control group and similar to the negative control
group. The SCFA acetate is produced in much greater amounts compared to propionate and
butyrate and appears to be the major reason for the lower cecal contents pH for the positive control
group.
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Antibiotic treatment resulted in a reduction of Lactobacillus spp. and Bifidobacterium spp.
However, the combination of resistant starch and antibiotic treatment in study 1.2 with either low
or high fat diets maintained similar amounts of Bacteroides spp. as the positive control group,
LFRS+NAB . Additionally, use of primers predominantly for Clostridium cluster XIVa and b
bacteria were not knocked down for groups treated by low potency antibiotics. Interestingly, the
antibiotic treatment with the low fat diet was not different from the positive control group
regarding total bacteria reflecting Bacteroides spp. (with Prevotella spp. and Poryphromonas spp.)
and likely other bacteria not measured. Similarities in Bacteroides spp. were also reflected in
similar production of propionate as Bacteroides spp. are major producers of propionate. Thus, the
low potency antibiotics used in the current studies appear to cause a shift in bacterial populations,
rather than a reduction of bacteria in general.
The results observed in study 1.2 for the targeted bacteria match the results observed for
SCFAs production. Bifidobacterium spp and Lactobacillus spp. bacteria fermentation products are
acetate and lactate. With low potency antibiotic treatment acetate production for both groups given
antibiotics (LFRS+AB and HFRS+AB) was diminished compared to the positive control group
(LFRS+NAB). Lactate was not measured in this study. In addition, Clostridium cluster XIVa and
b use acetate and lactate to produce butyrate. In this case Clostridium cluster XIVa and b bacteria
were not reduced by the low potency antibiotic treatment, but groups given antibiotics might not
have adequate acetate and lactate to produce levels of butyrate with feeding of resistant starch.
This resulted in low butyrate production for groups given antibiotics with levels even lower than
the negative control group. However propionate production for the group fed resistant starch in a
low fat diet and given antibiotics had the greatest numerical amounts that were statistically similar
to those for the positive control group. The positive control group had propionate levels that fell
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between the two groups treated with antibiotics and statistically similar with both groups. This
reflects the results for Bacteroides spp. and means that the low potency antibiotics treatment allows
these species to feed on the resistant starch granule as they normally do without antibiotics.
In phase 1 from study 1.1, we expected a greater ECW for RS+NAB group than NRS+AB
group due to previous data from our lab demonstrating increased ECW for rats fed resistant starch
[31, 66]. But ECW for the groups were not significantly different, even though one group was fed
resistant starch. Also, in study 1.2 it was observed again that groups given antibiotic treatment had
greater ECW than the negative control group (LFNRS+NAB) and similar to the positive control
group (LFRS+NAB). These results are likely the consequence of antibiotic treatment as another
study reported cecal dilation and increased osmotic activity of the cecal contents in rodents treated
with antibiotics [73]. This was partially confirmed by histology examination with numerically
greater cecal cell wall size for a rat from each of the two antibiotic treatment groups and a rat from
the positive control group compared to the negative control group.
Previous research done in our lab demonstrated that high fat in the diet partially attenuates
the ability to ferment resistant starch [66]. In study 1.2, we demonstrated that resistant starch in
low or high fat diets was not fermented in the cecum of the large intestine in the presence of low
potency antibiotics. For study 1.2 we had two alternative hypotheses. The first was that the
antibiotics should reduce fermentation. The second was that these low potency antibiotics may
actually improve the fermentation of resistant starch. Cani et al. demonstrated a decrease in gram
negative bacteria and decreased inflammatory endotoxemia with these antibiotics [51]. However,
in our study, fermentation was knocked out regardless of the level of fat in the diet.
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Low potency antibiotics also stimulated increased production of GLP-1 in our study.
Similarly, other studies had reported that antibiotics stimulate over-secretion of GLP-1 active from
intestinal cells [74, 75]. In like manner, other researchers had reported that vancomycin and
bacitracin improved insulin resistance because of augmentation of GLP-1 secretion even in rodents
that had diet-induced obesity [76].
Limited histological examination in study 1.2 revealed some explanation for why antibiotic
treatment might increase the ECW in rats. The muscularis layer may be increased with antibiotics
and the submucosa layer decreased, but the overall height of the cecal wall appears to be somewhat
greater than the negative control and less than the positive control. Other factors such as amount
of water in the cecal wall, not measured in this study, may be responsible for the lack of difference
for ECW between groups treated with antibiotics and the positive control group. Other studies
have demonstrated similar results of antibiotics on cecum weight [73]. This effect of antibiotics
on ECW means that this measure of fermentation cannot be used to document fermentation when
antibiotics are used, but researchers can still rely on cecal contents pH and production of acetate
and butyrate.
Finally, low potency antibiotics such as neomycin and ampicillin were able to reduce
fermentation of resistant starch when they are given at the same time as the feeding of the resistant
starch. This means that stronger potency antibiotics that come with possible greater risks of side
effects are not necessary to reduce fermentation of resistant starch when they are given at the same
time. It is also encouraging that feeding resistant starch without probiotic treatments appears to
promote almost full recovery of the targeted bacteria after treatment with antibiotics as
demonstrated by improvements in fermentation markers. However, treatment with more potent
antibiotics may cause more damage to the microbiota and require probiotic treatment. Future
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studies are warranted for expanding our knowledge on recovery of the microbiota after antibiotic
treatments. One of our main objectives was to determine if we could reduce fermentation of
resistant to be able to demonstrate effects of feeding resistant starch beyond the effects of
fermentation. However, increased empty cecum weights and increased GLP-1 active are a concern
for the future use of antibiotics for reduction of fermentation. Other methods such as
bacteriophages with lytic peptides that kill specific bacteria may be more targeted and not have
such broad effects as the use of antibiotics [77].
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CHAPTER 4: GENE EXPRESSION FOR INTESTINAL GLUCONEOGENESIS
ENZYMES IN THE FED AND FASTED STATE AFTER RESISTANT STARCH
FEEDING
4.1. Introduction
Resistant starch is a fermentable fiber that lowers the glycemic index of the diet because it
resists digestion in the small intestine [78]. It is fermented in the large intestine by bacteria that
produce short chain fatty acids (SCFAs) mainly as acetate, propionate, and butyrate [16].
Previously, we showed that resistant starch can decrease body fat accumulation, increase fat
oxidation, increase glucagon-like peptide 1 (GLP-1) cecal gene expression and plasma levels, upregulate peptide YY (PYY) gene expression and plasma levels, and affect expression of other
genes [29, 30, 79]. GLP-1 is an incretin that increases metabolic activity and improves insulin
sensitivity [80]. Robertson et al. showed improved insulin sensitivity in humans with [81] and
without increased GLP-1 compared to control subjects [18]. Some people do not produce as much
GLP-1 as others due to a defective transcription factor [82]. Therefore, it is important to study how
insulin sensitivity can be improved without increased GLP-1.
Animal studies consistently have shown increases of GLP-1 active and proglucagon gene
expression in response to resistant starch feeding [29, 31, 83]. On the other hand, the majority of
human studies have not shown greater concentrations of endogenous GLP-1 in response to
resistant starch feeding [34, 52, 84]. These outcomes in human studies might be due to the resistant
starch feeding time lasting only a few hours; which is different from animal studies where the
consumption of resistant starch lasts for weeks. However, beneficial effects of feeding resistant
starch have been observed in humans that include improvement in insulin sensitivity [34, 52],
increased insulin secretion [85], and increased satiety [86]. Additionally, resistant starch has shown
improved insulin sensitivity in the periphery (adipose and muscle) but not reduced hepatic glucose
production in subjects at risk of developing type 2 diabetes [33].
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Previously, the intestine has been described as a gluconeogenic organ due to its endogenous
glucose production capacity [87]. Therefore, intestinal gluconeogenesis (IGN) might have the
ability to decrease hunger and food intake [88]. It is proposed that certain diets such as proteinenriched [88-90], fiber-enriched [54], or certain procedures such as gastric bypass surgery [91] can
trigger IGN. De Vadder et al. demonstrated IGN increased as a result of fermentation of fructooligosaccharide (FOS) to butyrate, and propionate. IGN (presence of glucose in the portal blood)
leads to signaling from the gut to the brain to reduce hepatic gluconeogenesis for better glycemic
control and insulin sensitivity [54]. Our objective was to determine if feeding resistant starch
would result in increased IGN gene expression. To accomplish this objective we conducted two
studies and tested gene expression for proglucagon (GCG), pyruvate carboxylase (PCase), and
glucose-6-phosphatase (G6Pase). Proglucagon was used as a positive control by contrasting its
gene expression with plasma levels of GLP-1 active found in both studies. PCase is a mitochondrial
non-regulatory enzyme involved in gluconeogenesis that catalyzes the carboxylation of pyruvate
to form oxaloacetate the first step of IGN in the mitochondria [92]. G6Pase is a key regulatory
enzyme catalyzing the last step of gluconeogenesis to hydrolyze glucose-6-phosphate into glucose
and Pi in the cytoplasm [93]. Much more is known about gluconeogenesis in the small intestine
[93]. However, De Vadder et al. have reported increased gluconeogenesis in the large intestine in
mice fed FOS. Our goal was to determine if there was increased gluconeogenesis in response to
feeding resistant starch as either a pure starch or in whole grain flour. In GK rats we investigated
the fasted state (saline injection) and modeled the fed state with injection of insulin. In study 2.1,
fermentation indicators of resistant starch such as cecal contents pH and SCFAs production are
reported in Goto-Kakizaki (GK) rats. In study 2.2, Sprague Dawley rats fed either moderate or
high fat diets, as part of a larger study that will be reported later, were used in the fed state to
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determine if there was increased gene expression for IGN. In both studies GCG, PCase and G6Pase
gene expression were assessed.
4.2. Research Design and Methods
Animals and diets
For both studies, male rats were purchased at 6 weeks old and maintained in quarantine for
1 week. For the studies, rats were individually housed in wire bottom cages in a climate-controlled
environment (21-22°C, 55% humidity) with a 12:12 hour light-dark cycle. Rats were fed ad libitum
and had free access to water. Body weight, food intake and food spillage were measured twice a
week.
Study 2.1. Protocol was approved by the Pennington Biomedical Research Center
Institutional Animal Care and Use Committee. Forty eight (n=48), GK rats were purchased from
Charles River Laboratories International Inc. (Wilmington, MA). After quarantine, the GK rats
were fasted the night before blood draw for ~ 12 hours after allowing access to food for three hours
in the dark cycle (7-10 pm). Blood samples were obtained through retro-orbital bleeding, using
inhalation of 5% isoflurane as anesthesia, for measuring glucose and insulin values using
AlphaTRAK glucometer (Abbott Laboratories Inc., IL) and insulin kit (Millipore, MA),
respectively. Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated with
the measurements obtained by the following formula:
𝑚𝑔
µ𝑈
𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑝𝑙𝑎𝑠𝑚𝑎 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 ( 𝑑𝑙 ) × 𝑝𝑙𝑎𝑠𝑚𝑎 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 ( 𝑚𝑙 )
𝐻𝑂𝑀𝐴 − 𝐼𝑅 =
2430
Then 12 rats each were designated to one of the four isocaloric diets (3.23 kcal/g) based on
their weight and HOMA-IR. The study lasted 12 weeks and the diets were designated by their
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major ingredient: (1) Amylopectin control corn starch with no whole grain or resistant starch
(CON), (2) isolated high amylose maize resistant starch (HAMRS) corn starch (RS), (3) whole
grain waxy corn flour with low resistant starch (WG), and (4) whole grain HAMRS corn flour
(WG+RS). The composition of the four diets used is listed in Table 4.1. Purified non-fermentable
cellulose (Dyets, PA) was used to dilute the energy density of the control diets, non-whole grain
and whole grain, to produce isocaloric control diets as high resistant starch diet ingredients have a
lower metabolizable energy than amylopectin starch in isolated starch and waxy whole grain corn
flour [17]. Before diets were formulated, the starch and whole grain ingredients were analyzed by
proximate analysis and modified Englyst [94] assay to determine macronutrient and resistant
starch content, respectively. Casein was reduced from AIN-93M amount (140 g/kg) based on the
protein content in the major ingredient of each diet as analyzed by proximate analysis by Medallion
Labs for Ingredion Incorporated. Also, corn oil was 10% higher than AIN-93M amount (40 g/kg)
based on the fat content in whole grain HAMRS corn flour.
Table 4.1. Diets composition for Study 2.1.
CON1
Grams

RS
Grams

WG
Grams

WG+RS
Grams

536.80

97.66

85.98

164.50

High-amylose corn starch

0.00

576.00

0.00

0.00

Whole grain high-amylose corn flour4

0.00

0.00

0.00

572.00

0.00
100.00

0.00
100.00

550.00
100.00

0.00
100.00

136.00
135.00

132.27
7.00

95.42
97.20

74.80
40.50

44.00
35.00
10.00
1.40
1.80

38.87
35.00
10.00
1.40
1.80

23.20
35.00
10.00
1.40
1.80

0.00
35.00
10.00
1.40
1.80

Ingredients
Waxy corn starch2
3

Waxy whole grain flour
Sucrose
Casein6
Cellulose
Corn Oil7
Mineral mix
Vitamin mix
Choline chloride
L-Cystine

5
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(Table 4.1. Con’d)
Ingredients
Total
Total energy (kcal)

CON1
Grams
1000.00
3.24

RS
Grams
1000.00
3.24

WG
Grams
1000.00
3.24

WG+RS
Grams
1000.00
3.24

% RS8
1.00
26.47
6.10
26.79
1
Groups include: CON= Amylopectin control corn starch with no whole grain or resistant starch,
RS= isolated high amylose maize resistant starch (HAMRS) corn starch, WG= whole grain waxy
corn flour with low resistant starch, and WG+RS = whole grain HAMRS corn flour.
2
AMIOCA® corn starch
3
HI-MAIZE® resistant corn starch
4
HI-MAIZE® whole grain corn flour
5
Waxy corn starch, high-amylose corn starch, whole grain high-amylose corn flour and waxy
whole grain were all gifts from Ingredion Incorporated (Bridgewater, NJ).
6
Casein was reduced from AIN-93M amount (140 g/kg) based on the protein in the AMIOCA®
corn starch, HI-MAIZE® resistant corn starch, HI-MAIZE® whole grain corn flour, and waxy
whole grain as analyzed by proximate analysis by Medallion Labs for Ingredion Incorporated.
7
Corn oil was increased from AIN-93M amount (40 g/kg) to 44 g/kg based on the fat in the HIMAIZE® whole grain corn flour, and waxy whole grain flour as analyzed by proximate analysis
by Medallion Labs for Ingredion Incorporated. And corn oil was adjusted based on fat in the
main ingredients.
8
Resistant starch content of the four experimental starch ingredients determined by Ingredion
Incorporated using the modified Englyst assay [94].
Study 2.2. Protocol was approved by the Louisiana State University Institutional Animal
Care and Use Committee. Sprague Dawley rats (n=96) were purchased from Harlan Laboratories
Inc. (Indianapolis, IN). After quarantine twelve rats were assigned into one of the four isocaloric
diets for high fat content (4.18±0.02 kcal/g, 42.48%±0.17 of total energy) or into one of the four
isocaloric diets for moderate fat content (3.76±0.002 kcal/g, 30.10%±0.04 of total energy) based
on their body weight. The diets, within high fat or moderate fat content, were designated by the
major ingredient the same as in study 2.1 as: (1) CON, (2) RS, (3) WG, and (4) WG+RS. The
composition of the eight diets used is listed in Table 4.2.
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Table 4.2. Diets composition for Study 2.2.
1

Ingredients

CON
Grams

Waxy corn starch2

MODERATE FAT
RS
WG
Grams
Grams

WG+RS
Grams

473.30

72.31

63.83

137.74

High-amylose corn starch3

0.00

524.00

0.00

0.00

Whole grain high-amylose corn flour4

0.00

0.00

0.00

520.00

0.00
100.00

0.00
100.00

500.00
100.00

0.00
100.00

136.00
115.00

133.12
0.00

99.42
81.00

80.56
27.00

85.00
42.50
35.00
10.00
1.40
1.80
1000.00
3.76

79.87
42.50
35.00
10.00
1.40
1.80
1000.00
3.75

65.05
42.50
35.00
10.00
1.40
1.80
1000.00
3.76

44.00
42.50
35.00
10.00
1.40
1.80
1000.00
3.76

0.42

23.37

4.93

23.45

HIGH FAT
RS
WG
Grams
Grams

WG+RS
Grams

Waxy whole grain flour
Sucrose

5

Casein6
Cellulose
Corn Oil7
Lard
Mineral mix
Vitamin mix
Choline cloride
L-Cystine
Total
Total energy (kcal)
% RS8

1

Ingredients

CON
Grams

Waxy corn starch2

405.80

0.00

0.00

77.85

High-amylose corn starch

0.00

524.66

0.00

0.00

Whole grain high-amylose corn flour4

0.00

0.00

0.00

525.00

0.00
100.00

0.00
100.00

517.00
100.00

0.00
100.00

136.75
110.00

133.70
0.00

98.74
56.91

80.58
10.00

99.25
100.00
35.00
10.00
1.40
1.80
1000.00
4.16

93.44
100.00
35.00
10.00
1.40
1.80
1000.00
4.14

79.15
100.00
35.00
10.00
1.40
1.80
1000.00
4.23

58.37
100.00
35.00
10.00
1.40
1.80
1000.00
4.21

3

Waxy whole grain flour
Sucrose
Casein6
Cellulose
Corn Oil7
Lard
Mineral mix
Vitamin mix
Choline cloride
L-Cystine
Total
Total energy (kcal)

5
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(Table 4.2. Con’d)
Ingredients

1

CON
Grams

HIGH FAT
RS
WG
Grams
Grams

WG+RS
Grams

% RS8
0.36
23.32
5.04
23.41
1
Groups include: CON= Amylopectin control corn starch with no whole grain or resistant starch,
RS= isolated high amylose maize resistant starch (HAMRS) corn starch, WG= whole grain waxy
corn flour with low resistant starch, and WG+RS= whole grain HAMRS corn flour.
2
AMIOCA® corn starch
3
HI-MAIZE® resistant corn starch
4
HI-MAIZE® whole grain corn flour
5
Waxy corn starch, high-amylose corn starch, whole grain high-amylose corn flour and waxy
whole grain flour were all gifts from Ingredion Incorporated (Bridgewater, NJ).
6
Casein was reduced from AIN-93M amount (140 g/kg) based on the protein in the AMIOCA®
corn starch, HI-MAIZE® resistant corn starch, HI-MAIZE® whole grain corn flour, and waxy
whole grain as analyzed by proximate analysis by Medallion Labs for Ingredion Incorporated.
7

In moderate fat (30% of energy) diets, one-third of the fat was lard and two-thirds was corn
oil. For high fat (42.48% of energy) diets one-half of the fat was lard and the other half was corn
oil. Based on the proximate analysis of AMIOCA® corn starch, HI-MAIZE® resistant corn
starch, HI-MAIZE® whole grain corn flour, and waxy whole grain flour as analyzed by
proximate analysis by Medallion Labs for Ingredion Incorporated, the corn oil was reduced.
8

Resistant starch content of the four experimental starch ingredients determined by Ingredion
Incorporated using the modified Englyst assay [94].
Procedures
Study 2.1. During week 8, fed state blood samples were collected by retro-orbital bleeding
to measure GLP-1 active with ELISA kit (ALPCO, NH). At week 10 another fasted blood
collection was performed in order to repeat calculations for HOMA-IR. After 12-weeks GK rats
were fasted again for euthanasia. Fifteen minutes prior to euthanasia the next day, 6 rats per
treatment were given an intraperitoneal (IP) injection of saline solution (fasted state) and the other
6 rats were injected with 1.00 unit/kg of insulin to model the fed state.
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In studies 2.1 and 2.2, rats were euthanized by cardiac puncture using inhalation of
isoflurane soaked cotton balls as anesthesia in a bell jar. Fat pads (peritoneal, retroperitoneal, and
epididymal) were removed and weighed for total abdominal fat percentage (ABF %) calculation.
The gastro-intestinal (GI) tract was removed from esophagus to anus and weighed after removal
of mesenteric fat. Emboweled weight for ABF% was obtained after subtraction of GI contents
from body weight. Cecal contents and cecal epithelial cells, collected by scraping, were frozen in
liquid nitrogen to analyze later. For studies 2.1 and 2.2, gene expression for GCG, G6Pase and
PCase enzymes for IGN were measured, but that is the only data reported here for study 2.2.
Cecal contents pH and short-chain fatty acid analysis
For study 2.1, cecal contents were thawed and homogenized in distilled water (0.5 g wet
sample to 5 ml of water), for pH measurements. Next, each sample was acidified with 1 ml of a
25% (w/w) solution of metaphosphoric acid containing 2 g/L 2-ethyl-butyric acid as an internal
standard for SCFA contents. Solids were separated by centrifugation and filtration. The
supernatant was transferred to a GC auto-sampler vial. Concentrations of SCFA were
quantitatively determined by gas chromatography by a method described in a previous publication
from our laboratory [66].
Measurement of mRNA expression
Approximately, 20 to 30 mg of cecal epithelial cells were cut using a super-cold (dry ice)
blade for each rat’s sample and placed into an ice cold 2 ml Lysing Matrix D tube (MP
Biomedicals, OH) with 1.4 mm ceramic spheres and 600 µl RLT lysis buffer from RNeasy Mini
Kit (Qiagen, Germany). Immediately, the tubes with the epithelial cells, lysis buffer and ceramic
spheres were homogenized using a FastPrep®-24 Instrument (MP Biomedicals, OH) for 30
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seconds at speed setting 6.0 m/s. The lysate was centrifuged for 3 minutes at 14,000 rpm, and total
RNA was extracted from the supernatant by following the RNeasy Mini Kit protocol. RNA was
quantified using a NanoDrop® ND-1000 spectrophotometer (Wilmington, DE) and diluted to 40
ng/ µl. The gene transcription for GCG as positive control, PCase, and G6Pase for both studies,
were determined using real-time reverse transcriptase polymerase chain reaction (real-time RTPCR) using ABI PRISM 7900 Sequence Detection System, and SDS 2.4 software (Life
Technologies, NY). Standard curves were produced for each mRNA by pooling aliquots of
samples for cycles to threshold versus RNA amount. The results were expressed as a ratio to the
expression of cyclophilin (CYC). The sequences of TaqMan probes and primers for cyclophilin
(GenBank accession no. M15933) were: (5’-3’) forward primer, CCCACCGTGTTCTTCGACAT;
reverse primer, TGCAAACAGCTCGAAGCAGA; and probe, CAAGGGCTCGCCATCAGCCG.
The probe and primers for proglucagon, G6Pase, and PCase were from Life Technologies (Foster
City, CA). Each sample was tested in triplicate. The real-time RT-PCR conditions for all genes
were 48°C for 30 min, 95°C for 15 s and 60°C for 1 min for 40 cycles.
Statistical Analysis
Data for both studies were analyzed using Statistical Analysis Software SAS® version 9.3.
Equal variance, normal distribution, and possible outliers were tested by an UNIVARIATE
procedure used in the MIXED procedure. Food intake, HOMA-IR at week 10, and GLP-1 data
sets from study 2.1 were analyzed and statistical differences among groups were determined by a
2 x 2 factorial followed by F-protected LSD post-hoc mean comparison tests using the MIXED
procedure. A p< 0.05 was considered statistically significant. The two factors were resistant starch
(R, low or high), and whole grain (W, + or -). These data were collected before insulin injection.
Only HOMA-IR was log 10 transformed from original data for statistical analyses due to non-
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normal distribution (w<0.05) according to Shapiro-Wilk test. Data variables from study 2.1
collected at euthanasia were analyzed as 2 x 2 x 2 factorials. The three factors were resistant starch
(R, low or high), whole grain (W, + or -), and injection (I, insulin or saline). Outliers were detected
and removed for GLP-1 active (CON: 1.51, 1.97; RS: 2.52; WG: 1.49; WG+RS: 0.31), pH
(WG+RS: 7.31), acetate (RS: 0.89; WG: 0.21), propionate (RS: 0.15; WG: 0.03), GCG:CYC
(CON: 3.99), G6Pase:CYC (CON: 19.21, 6.93; RS: 3.50; WG: 0.06; WG+RS: 7.97). Acetate,
propionate, butyrate, GCG:CYC, PCase:CYC, and G6Pase:CYC dependent variables were log 10
transformed from original data for statistical analyses due to non-normal distribution (w<0.05)
according to Shapiro-Wilk test. GLP-1 active, ABF%, cecal contents pH, and empty cecum weight
(ECW) data sets were not log 10 transformed. Data for analysis of IGN for study 2.2 reported here
were a 2 x 2 x 2 factorial and the variables were R (low or high), W (+ or -), and Fat (F, moderate
or high). GCG:CYC, PCase:CYC, and G6Pase:CYC dependent variables were log 10 transformed
for statistical analyses because they were not normally distributed (w<0.05) according to ShapiroWilk test from original data. All factorial data were followed by F-protected LSD post-hoc mean
comparison tests. Data are presented in their original form and expressed as means ± standard
error. Correlations were performed using the CORR procedure.
4.3. Results
Study 2.1.
Food intake, HOMA-IR, and GLP-1 Active
Food intake (Fig 4.1.) over the study was increased by presence of dietary whole grain
(p<0.0348) in the diet. WG and WG+RS groups registered the highest consumptions and they were
not significantly different (p=0.7576) from one another. No significant effect for dietary resistant
starch (p=0.2886) or interaction effect of dietary whole grain*dietary resistant starch (p=0.1374)
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were documented. CON group consumed less food compared to WG (p<0.0123) and WG+RS
(p<0.0263) groups. Additionally, the RS group approached a significant increase in food intake
from CON group (p=0.0741). The RS group was not significantly different from WG (p=0.4391),
and WG+RS (p=0.6405) groups.

1800.00

a
ab

1750.00

a

Food Intake (g)

1700.00

1650.00

b

1600.00

1550.00

1500.00

1450.00
CON

RS

WG

WG+RS

Figure 4.1. Food Intake for Study 2.1. Groups include: CON = Amylopectin control corn starch
with no whole grain or resistant starch, RS = isolated HAMRS corn starch, WG = whole waxy
corn flour with low RS, and WG+RS = whole grain HAMRS corn flour. Data are presented in
their original form and expressed as means ± standard error. Different letters above columns
indicate a statistically significant difference p<0.05 for a 2 x 2 factorial. A main effect of W
(p<0.0348) was observed.
There was a main effect of feeding high resistant starch (p<0.0001) as dietary high resistant
starch resulted in lower HOMA-IR (greater insulin sensitivity in fasted state) for RS and WG+RS
groups compared to the control groups (CON, WG). However, WG+RS had a greater value than
RS (p<0.0014) as a result there was a whole grain effect (p<0.0057) dominated by high resistant
starch in whole grain diet and resistant starch effect (p<0.0001). This resulted in an interaction for
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wholegrain*resistant starch (p=0.0628) approaching significance. CON and WG groups had the
highest HOMA-IR and were not significantly different (p=0.4839) from each other (Fig. 4.2).
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a

HOMA-IR

2.00

b
c

1.50

1.00

0.50

0.00

CON

RS

WG

WG+RS

Figure 4.2. HOMA-IR for Study 2.1. Groups include: CON = Amylopectin control corn starch
with no whole grain or resistant starch, RS = isolated HAMRS corn starch, WG = whole waxy
corn flour with low RS, and WG+RS = whole grain HAMRS corn flour. Data are presented in
their original form and expressed as means ± standard error. Different letters above columns
indicate a statistically significant difference p<0.05. Data are shown on two factors, resistant starch
(R, low or high) and whole grain (W, + or -) from 2 x 2 factorial. Main effects for W (p<0.0057)
and R (p<0.0001), but no interaction for W*R (p=0.0628) were documented.
GLP-1 active (Fig 4.3.) measured in the fed state demonstrated a resistant starch effect
(p<0.0001) as the RS and WG+RS groups fed high resistant starch were greater compared to CON
and WG groups. There was no effect of whole grain (p=0.5929) as WG+RS was no different than
RS (p=0.4876) and the control groups CON and WG were the lowest and not significantly different
(p=0.5873) from one another. This also resulted in no interaction of whole grain*resistant starch
(p=0.4179). GLP-1 active was negatively correlated with HOMA-IR (p=0.0361).
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a
a

1.20

GLP-1 Active (pM)

1.00
0.80
0.60

0.40
0.20

b

b

0.00
CON

RS

WG

WG+RS

Figure 4.3. GLP-1 active for Study 2.1. Groups include: CON = Amylopectin control corn starch
with no whole grain or resistant starch, RS = isolated HAMRS corn starch, WG = whole waxy
corn flour with low RS, and WG+RS = whole grain HAMRS corn flour. Data are presented in
their original form and expressed as means ± standard error. Different letters above columns
indicate a statistically significant difference 0.05. Data are shown on two factors, resistant starch
(R, low or high) and whole grain (W, + or -) from 2 x 2 factorial. Main effect for R (p<0.0001)
was observed.
Abdominal fat percent (ABF %), cecal contents pH, SCFAs
For ABF % there was a main effect of dietary resistant starch (p<0.0001), and interaction
effects for dietary whole grain*dietary resistant starch (p<0.0119) and dietary whole
grain*injection (p<0.0327). The significant effect for resistant starch is the result of the RS group
having the lowest value of all groups with saline injection, and RS group having a numerically
lower value than WG and WG+RS and significantly lower than CON with insulin injection. The
whole grain*resistant starch interaction was the result of the WG+RS group having a higher value
than RS group with saline injection. The significant whole grain*injection interaction was the
result of the WG+RS and WG groups having numerically lower values with the insulin injection
compared with saline injection (Fig. 4.4.).
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Figure 4.4. Abdominal fat percent (ABF %) for Study 2.1. Groups include: CON = Amylopectin
control corn starch with no whole grain or resistant starch, RS = isolated HAMRS corn starch, WG
= whole grain waxy corn flour with low resistant starch, and WG+RS = whole grain HAMRS corn
flour. Data are presented in their original form and expressed as means ± standard error. Different
letters above columns indicate a statistically significant difference at p<0.05. Data are shown on
three factors, resistant starch (R, low or high), whole grain (W, + or -), and Injection (I, insulin or
saline) for a 2 x 2 x 2 factorial. A main effect for R (p<0.0001), and interactions for W*R
(p<0.0119) and W*I (p<0.0327) were documented.
For cecal contents pH (Fig. 4.5) there were significant main effects for dietary whole grain
(p<0.0001), dietary resistant starch (p<0.0001), and injection (p<0.0089), as well as interaction
effects of dietary whole grain*dietary resistant starch (p<0.0001), dietary whole grain*injection
(p<0.0027) and dietary whole grain*dietary resistant starch*injection (p<0.0048). The resistant
starch effect occurred because the lowest cecal contents pH was for the RS group with both saline
and insulin injections. The whole grain main effect and interaction effects are the result of the
WG+RS group having lower cecal contents pH than the two control groups (CON, WG), but not
the RS group with the insulin injection. Additionally, the WG control group had lower pH than the
isolated starch group CON with both types of injections (insulin p<0.0363, saline p<0.0095).
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Figure 4.5. Cecal contents pH, and SCFA propionate for Study 2.1. Groups include: CON =
Amylopectin control corn starch with no whole grain or resistant starch, RS = isolated HAMRS
corn starch, WG = whole grain waxy corn flour with low resistant starch, and WG+RS = whole
grain HAMRS corn flour. Data are presented in their original form and expressed as means ±
standard error. Different letters above columns indicate a statistically significant difference at
p<0.05. Data are shown on three factors, resistant starch (R, low or high), whole grain (W, + or ), and Injection (I, insulin or saline) for a 2 x 2 x 2 factorial. Main effects for W (p<0.0001), R (p
<0.0001) and I (p<0.0089); and interactions for W*R (p<0.0001), W*I (p<0.0027) and W*R*I
(p<0.0048) were observed.
There were significant main effects for dietary whole grain (p<0.0248), dietary resistant
starch (p<0.0001) and injection (p<0.0477) and significant interactions for dietary whole
grain*dietary resistant starch (p<0.0001) for production of the SCFA propionate in cecal contents
(Fig 4.6.). The reasons for the significant main effects and interaction effect are: propionate was
produced to a much greater extent in cecal contents of the RS group regardless of the type of
injection compared to the other groups, but the amount was reduced with insulin injection
compared to saline injection; and the WG+RS (saline or insulin p<0.0001) and WG (saline
p<0.0312, insulin p<0.0075) groups had greater amounts than CON regardless of type of injection.
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Figure 4.6. Millimoles of SCFA propionate in cecal contents Study 2.1. Groups include: CON =
Amylopectin control corn starch with no whole grain or resistant starch, RS = isolated HAMRS
corn starch, WG = whole grain waxy corn flour with low resistant starch, and WG+RS = whole
grain HAMRS corn flour. Data are presented in their original form and expressed as means ±
standard error. Different letters above columns indicate a statistically significant different at
p<0.05 Data are shown on three factors, resistant starch (R, low or high), whole grain (W, + or -),
and Injection (I, insulin or saline) for a 2 x 2 x 2 factorial. A main effect for I (p<0.0477) was
reported, for that reason data were not collapsed. There were main effects of W (p<0.0248) and
R (p<0.0001), and an interaction effect for W*R (p<0.0001) observed.
Statistical analysis for ECW and the SCFAs acetate and butyrate (Table 4.3.) were
collapsed from eight to four groups, since no main effect or significant interaction was documented
for injection. The ECW was increased in the presence of high resistant starch in the diet (p<0.0001)
as RS and WG+RS groups had higher empty cecum weights compared to CON and WG groups.
The RS group had a greater value than WG+RS group (p<0.0001) and there was also a dietary
resistant starch*dietary whole grain effect (p<0.0001). This interaction was dominated by high
resistant starch because its addition to a whole grain diet increased the ECW. The presence of high
resistant starch (dietary resistant starch effect, acetate p<0.0001 and butyrate p<0.0001) in diets
increased the production of acetate and butyrate for groups fed high resistant starch diets (RS,
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WG+RS). There was also a resistant starch*whole grain effect (p<0.0001) because acetate and
butyrate in cecal contents were greater when there was whole grain resistant starch in the diet.
Additionally, the WG group had greater production than CON group (acetate p<0.0004, and
butyrate p<0.0009).
Table 4.3. ECW, Acetate, and Butyrate for Study 2.11.
Groups2
P value1, 3,4
Variables
CON
RS
WG WG+RS
W
R
W*R
5
ECW (g)
0.52c 1.64a 0.54c
1.15b
0.0001 <.0001 <.0001
Acetate (mmol)
0.32d 4.22a
0.6c
1.92b
0.5924 <.0001 <.0001
Butyrate (mmol)
0.04d 0.53a 0.11c
0.23b
0.8348 <.0001 <.0001
1
Data are shown collapsed on two factors, resistant starch (R, low or high) and whole grain (W,
+ or -) for a 2 x 2 factorial because there were no significant effects of the third factor, Injection
(I, insulin or saline). All markers of fermentation had a significant effect of R and some had
significant effects of W. Acetate and butyrate data were log10 transformed for statistical
analysis.
2
Groups include: CON = Amylopectin control corn starch with no whole grain or resistant starch,
RS = isolated high amylose maize resistant starch (HAMRS) corn starch, WG = WG waxy corn
flour with low RS, and WG+RS = WG HAMRS corn flour. Data are presented in their original
form and expressed as means.
3
P value< 0.05 was considered statistically significant and it is represented with different letters
horizontally.
4
There were no interaction effects for: W*I, R*I and W*R*I (p>0.05).
5
ECW = Empty cecum weight.
Transcript levels in cecal cells
The statistical analyses for mRNA expression measurements were collapsed and listed for
the independent variables dietary resistant starch and dietary whole grain because there were no
main or interactive effects for injection. There was higher GCG:CYC gene expression for RS and
WG+RS groups (Fig. 4.7A) compared to CON and WG groups for a resistant starch effect
(p<0.0001). The RS group had greater (p<0.0075) GCG:CYC gene expression than WG+RS
resulting in whole grain effect (p<0.0299), which was dominated by resistant starch effect and
there was no interactive effect for whole grain*resistant starch (p=0.0999). Additionally, the
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injection effect approached significance (p=0.0518) because it was dominated by resistant starch
effect and whole grain effect. The PCase:CYC (Fig. 4.7B) and G6Pase:CYC (Fig. 4.7C) gene
expression had no significant main or interactive effects; therefore no significant differences were
found among the groups. However, for PCase:CYC the resistant starch effect approached
significance (p=0.0984).
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Figure 4.7. Transcript levels in cecal cells for Study 2.1. Groups include: CON = Amylopectin
control corn starch with no whole grain or resistant starch, RS = isolated HAMRS corn starch, WG
= whole grain waxy corn flour with low RS, and WG+RS = whole grain HAMRS corn flour. Data
are presented in their original form and expressed as means ± standard error. Different letters above
columns indicate a statistically significant difference at p<0.05. Data are shown collapsed on two
factors, resistant starch (R, low or high) and whole grain (W, + or -) for a 2 x 2 factorial because
there was no significant effect of the third factor, Injection (I, insulin or saline). A. Glucagon
(GCG):Cyclophilin (CYC) gene expression in cecal cells. Main effects for W (p<0.0299) and R
(p<0.0001) were documented. B. Pyruvate Carboxylase (PCase):CYC gene expression in cecal
cells. There were no main or interaction effects observed. Also, there were no significant
differences among treatment groups. C. Glucose-6 Phosphatase (G6Pase):CYC gene expression
in cecal cells. No main or interactions were observed. There were no significant differences among
groups.
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Study 2.2
Transcript levels in cecal cells
mRNA expression measurements for GCG and G6Pase were collapsed to resistant starch
and whole grain independent variables, because the level of fat in the diets did not affect the GCG
and G6Pase ratios to CYC for gene expression. Results from GCG:CYC ratio (Fig.4.8A.)
demonstrated that the RS group had the highest proglucagon gene expression resulting in a main
effect of resistant starch (p<0.0002). A main effect for whole grain (p<0.0367) and interactive
effect for whole grain*resistant starch (p<0.0012) were also observed, however, CON, WG and
WG+RS groups were not significantly different from one another. For G6Pase:CYC ratio there
was a significant resistant starch (Fig. 4.8B) effect (p<0.0001) as RS and WG+RS groups were not
significantly different (p=0.6952) from one another, but had greater ratios than control groups
(CON and WG). CON and WG groups were not significantly different (p=0.5853) from one
another, and these were reflected in no main effect for whole grain (p=0.5192) or interactive effect
for whole grain*resistant starch (p=0.9836). A higher PCase:CYC ratio was obtained for RS and
WG+RS groups (resistant starch effect, p<0.0001) compared to CON or WG with a moderate fat
diet (Fig. 4.8C). The PCase:CYC ratio was reduced for the RS group (resistant starch*fat,
p<0.0118), but not reduced significantly with WG+RS with the feeding of the high fat diet
(resistant starch*whole grain, p=0.6620). Also, the WG+RS and RS groups were not significantly
different (p=0.0847) from one another with high fat diet. There was a significant whole grain effect
(p<0.0294) because the WG group was numerically greater than CON for both moderate and high
fat diets and WG+RS group was numerically greater than RS with the high fat diet.
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Figure 4.8. Transcript levels in cecal cells for Study 2.2. Groups include: CON = Amylopectin
control corn starch with no whole grain or resistant starch, RS = isolated HAMRS corn starch, WG
= whole waxy corn flour with low RS, and WG+RS = whole grain HAMRS corn flour. Data are
presented in their original form and expressed as means ± standard error. Different letters above
columns indicate a statistically significant difference at 0.05. Glucagon (GCG):Cyclophilin (CYC)
and Glucose-6 Phosphatase (G6Pase):CYC data are shown collapsed on two factors, resistant
starch (R, low or high) and whole grain (W, + or -) for a 2 x 2 factorial because there was no
significant effect of the third factor, Fat (F, moderate or high). A. GCG:CYC gene expression in
cecal cells. Main effects for W (p<0.0367) and R (p<0.0002) and interaction for W*R (p<0.0012)
were documented. B. G6Pase:CYC gene expression in cecal cells. There was a main effect of R
(p<0.0001) observed. C. Pyruvate Carboxylase (PCase):CYC gene expression in cecal cells. Main
effects of W (p<0.0294) and R (p<0.0001) and an interaction of R*F (p<0.0118) were observed.
4.4. Discussion
As was stated in the introduction, humans fed resistant starch diets have exhibited the
beneficial health effect of improvement of insulin sensitivity, whether or not there was increased
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production of GLP-1 active [18, 81]. Therefore, other mechanisms such as IGN might be involved.
Rodent studies have reported insulin sensitivity improvements and decreased hepatic
gluconeogenesis with increased IGN [54]. In contrast, human studies have reported insulin
sensitivity improvements, increased glucose uptake in skeletal muscle and adipose, but no
reduction of hepatic gluconeogenesis [18, 33]. Decreased hepatic gluconeogenesis in rodents could
be a response of increased AMPK phosphorylation and activity due to SCFAs [14], and this
mechanism might not occur in humans. Additionally, there is no scientific research done in humans
for increased IGN as a result of a resistant starch feeding. It is known that not all findings in rodent
studies can be translated to humans, but there is strong evidence that production of SCFAs during
fermentation of resistant starch and other fermentable fibers provide beneficial health effects for
rodents and humans.29 Our results demonstrated that increased IGN gene expression occurred in
the fed state of Sprague Dawley rats, therefore we propose IGN as a possible mechanism that
improves insulin sensitivity in humans, but this needs to be confirmed in humans.
In Study 2.1, we investigated the fermentation effects of high resistant starch (isolated or
whole grain HAMRS forms), compared to highly digestible isolated starch and waxy whole grain
low resistant starch, on improving insulin sensitivity and gluconeogenic gene expression in cecum
for GK rats, a non-obese type 2 diabetic model [95]. This model has a reduced pancreatic mass
[32]. Our results demonstrated that high resistant starch as either isolated or in whole grain form
had similar effects with increased GLP-1 active, greater insulin sensitivity (lower HOMA-IR) and
greater fermentation (greater empty cecum weights, lower cecal contents pH, and greater SCFAs)
in GK rats. GLP-1 active secretion in plasma was stimulated by RS and WG+RS diets in
comparison with WG and CON diets. The increase of GLP-1 active was significantly negatively
correlated to HOMA-IR (p=0.0361). GLP-1 secretion is associated with improvements in glucose
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metabolism by stimulating glucose-dependent insulin secretion[80] and inhibition of glucagon
secretion [96]. We also previously demonstrated that isolated resistant starch feeding to GK rats
significantly improved insulin sensitivity [32], but hypothesized that whole grain may have a
greater effect. These results indicate that the beneficial effect on insulin sensitivity results from
presence of high resistant starch and was not due to other components in the whole grain. Also,
increased GLP-1 secretion is proposed to be the result of increased SCFAs (product from
fermentation of resistant starch or other fermentable fibers in the large intestine) binding to Gprotein-coupled receptors on GLP-1-secreting L cells in the colon [97]. Human studies have also
demonstrated that dietary resistant starch intake improves insulin sensitivity [98].
GK rats fed RS or WG+RS diet showed a decrease for ABF%. The reduced body fat
percent for RS or WG+RS groups suggested increased fat oxidation as food intake was increased
significantly for WG+RS and numerically for RS. Previous data from our lab demonstrated dietary
resistant starch boosted fat oxidation in mice [29]. No scientific literature was found to support
that insulin injection prior to euthanasia may affect ABF%, especially for whole grain diets and
for that reason further research is suggested. However, the WG+RS rats that had the insulin
injection had a lower cecal contents pH. Thus, by chance, the rats given the insulin injection
appear to have greater fermentation and this may be the reason for the lower ABF% with insulin
injection. Also, the presence of whole grain increased food intake in GK rats and presence of
resistant starch approached significance so there may have possibly been increased fat oxidation
and reduced abdominal fat pads [32] and reduced fat accretion in stores [98].
Body weight (data not shown) was not significantly different between the rats designated
for injection of saline or insulin, as there was no main effect for dietary whole grain (p=0.5655),
dietary resistant starch (p=0.7885) or interactive effect for dietary whole grain*dietary resistant
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starch (p=0.2485). In another rodent study there was also no decrease in total body weight in
response to resistant starch feeding [27]. These results might be a consequence of increased total
bowel contents, thickness of the lumen, and mass of microbiome [27]. However, rodent studies
have demonstrated reduction in total body fat percentage for resistant starch diets compared to a
highly digestible starch diet [29, 83, 99].
The WG group exhibited less fermentation compared to the RS and WG+RS groups which
demonstrated a greater or dominant effect of resistant starch compared to a whole grain effect on
empty cecum weight, and SCFAs. The WG+RS group had a lower cecal contents pH compared to
WG only with insulin injection. We hypothesized greater fermentation for whole grain because
whole grain has more complex dietary fiber composed of oligosaccharides, resistant starch, and
non-starch polysaccharides, and it has been shown to augment the production of SCFAs in the
large intestine, especially butyrate [100]. However, this did not occur in the current study. This
result did not occur in the present GK rat study likely because of the fasted state of the rats. It may
be suggested that the WG+RS diet may have a shorter transit time than the RS diet so that more
isolated resistant starch was present in the cecum at euthanasia.
IGN is a regulator of glucose and energy homeostasis [88]. De Vadder et al. reported that
the production of propionate and butyrate from fermentation of FOS activates IGN genes such as
G6Pase in small intestine (jejunum) and large intestine (colon) [54]. Sun et al. demonstrated that
duodenal-jejunal bypass upregulated G6Pase in small intestine in GK rats [101]. In studies 2.1 and
2.2 we examined the gene expression of G6Pase and PCase in cecum as indicators of IGN in large
intestine. The results of the studies demonstrated that resistant starch feeding results in increased
IGN gene expression only in the fed state with dietary resistant starch. In addition GCG gene
expression was measured as a positive control for real-time RT-PCR. In study 2.1, the increase of
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GLP-1 active was significantly positively correlated to GCG:CYC. RS and WG+RS had higher
gene expression of GCG compared to CON and WG as well as increased serum GLP-1 active.
Increased GCG [31] and GLP-1 [29] active have also been reported in previous studies.
Furthermore, in study 2.2 greater expressions of GCG gene and GLP-1 active in serum in Sprague
Dawley rats fed the RS diet were observed independent of fat level. However, the WG+RS group
did not have increased GCG gene expression, which suggests that this group was more efficient in
translation as the rats in the RS group because both groups similarly increased serum GLP-1 active
(data not shown).
Study 2.1 was planned to determine if resistant starch feeding would increase IGN gene
expression in the fasted and fed states, with injection of insulin as a model for the fed state. We
hypothesized that since FOS increased IGN, another fermentable fiber, resistant starch, should also
stimulate IGN. Then in study 2.2, we measured IGN gene expression in Sprague Dawley rats only
in the fed state. There was increased, gene expression of PCase and G6Pase, independent of fat
level, in cecal cells in rats fed the RS and WG+RS diets. Previous results demonstrated that high
fat diet partly diminished the fermentation in Sprague Dawley rats fed resistant starch [66], but in
study 2.2 there were similar increases in IGN gene expression regardless of level of dietary fat.
These results indicate that high resistant starch increased IGN gene expression in the large intestine
only in the fed state and that injection of insulin associated with the fasted state is not a good model
for the fed state in regard to IGN gene expression.
In summary, the present research study demonstrated that gene expression for two IGN
enzymes are increased in the fed state in the large intestine of Sprague Dawley rats fed RS and
WG+RS diets with either moderate or high fat. No increase in IGN enzyme gene expression was
detected in the large intestine of fasted GK rats fed high resistant starch or whole grain in a low
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fat diet, even though the insulin sensitivity was improved. IGN in the large intestine appears to
occur in the fed state and not if the rats are fasted. It also appears that insulin injection does not
model the fed state, in regards to IGN gene expression. However, the current data indicate that
Americans consuming a moderate or high fat diet can include resistant starch as a fermentable
fiber in their typical diet in order to increase IGN in the large intestine and benefit from better
glycemic control and insulin sensitivity. Further research needs to be done for IGN in large
intestine for Sprague Dawley rats to determine if increased IGN gene expression translates to
increased enzyme levels; and to measure IGN gene expression in the fed state in GK rats in
response to resistant starch consumption. Also, research is warranted to determine if IGN is
increased in human subjects fed resistant starch and may account for increased insulin sensitivity
when serum GLP-1 is not increased.
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CHAPTER 5: CONCLUSIONS
The results obtained in study 1.2 demonstrated that the usage of very potent antibiotics can
be avoided to reduce fermentation of resistant starch in the rat cecum for future mechanistic studies
with dietary resistant starch. In phase 1 of study 1.1 we determined that fermentation of resistant
starch was not knocked down if low potency antibiotics, neomycin and ampicillin, are given prior
to feeding resistant starch. In study 1.2 it was demonstrated that low potency antibiotics were able
to reduce total fermentation when they were given simultaneously with resistant starch feeding. In
future studies low potency antibiotics can be used to study beneficial effects of resistant starch
besides fermentation. Additionally, it was observed that neomycin and ampicillin stimulated the
secretion of GLP-1. This side effect might improve insulin resistance, but this and other effects of
antibiotics may not allow mechanistic studies with dietary resistant starch. However, it was
encouraging to us that effects of antibiotics were reversed by subsequent feeding of resistant starch
in phase 2 of study 1.1.
In study 2.2, it was demonstrated that high amylose corn starch and whole grain high
amylose corn flour in moderate and high fat diets promoted increased gene expression of enzymes
PCase and G6Pase in the fed state in the cecum of Sprague Dawley rats. Further study is necessary
to determine enzyme levels, but the current results are similar to results with feeding of fructooligosaccharide. Also, insulin injection prior to euthanasia of GK rats was not able to model the
fed state. Future studies are necessary to study if resistant starch in the diet promotes IGN also in
humans. Due to these findings, it was demonstrated that resistant starch in isolated form or whole
grain flour might promote a mechanism for better glycemic control and improvement of insulin
sensitivity for human subjects that do not produce increased GLP-1 active secretion in response to
the feeding of resistant starch.
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Nowadays, people’s life style is characterized by consumption of diets high in saturated fat
and almost no physical activity. This has consequences such as obesity and inflammatory diseases.
Therefore, it is important to add resistant starch as an ingredient in food products of daily
consumption not only to decrease energy density, but also to promote a healthier microbiota and
improve glucose control and insulin sensitivity. Also, the result of our research indicates another
mechanism for beneficial effects of resistant starch besides increasing GLP-1 and offers a possible
explanation for human subjects that have improved insulin sensitivity with the feeding of resistant
starch without increased GLP-1 compared to control subjects.

66

REFERENCES
1.

Brennan, C.S., Dietary fibre, glycaemic response, and diabetes. Molecular Nutrition &
Food Research, 2005. 49(6): p. 560-570.

2.

Ley, R.E., et al., Microbial ecology: Human gut microbes associated with obesity. Nature,
2006. 444(7122): p. 1022-1023.

3.

Zhang, D., Y. Huang, and D. Ye, Intestinal dysbiosis: An emerging cause of pregnancy
complications? Medical Hypotheses, (0).

4.

Chow, J., H. Tang, and S.K. Mazmanian, Pathobionts of the gastrointestinal microbiota
and inflammatory disease. Current Opinion in Immunology, 2011. 23(4): p. 473-480.

5.

Round, J.L. and S.K. Mazmanian, The gut microbiota shapes intestinal immune responses
during health and disease. Nat Rev Immunol, 2009. 9(5): p. 313-323.

6.

Seksik, P., Gut microbiota and IBD. Gastroentérologie Clinique et Biologique, 2010. 34,
Supplement 1(0): p. S44-S51.

7.

Hawrelak, J.A. and S.P. Myers, The causes of intestinal dysbiosis: a review. Altern Med
Rev, 2004. 9(2): p. 180-97.

8.

Turnbaugh, P.J., et al., An obesity-associated gut microbiome with increased capacity for
energy harvest. Nature, 2006. 444(7122): p. 1027-131.

9.

Cani, P.D., et al., Metabolic Endotoxemia Initiates Obesity and Insulin Resistance.
Diabetes, 2007. 56(7): p. 1761-1772.

10.

Chun, M.R., et al., Differential effects of high-carbohydrate and high-fat diet composition
on muscle insulin resistance in rats. J Korean Med Sci, 2010. 25(7): p. 1053-9.

11.

Slavin, J., Fiber and Prebiotics: Mechanisms and Health Benefits. Nutrients, 2013. 5(4):
p. 1417-1435.

67

12.

Crittenden, R., et al., In vitro fermentation of cereal dietary fibre carbohydrates by
probiotic and intestinal bacteria. Journal of the Science of Food and Agriculture, 2002.
82(8): p. 781-789.

13.

Pryde, S.E., et al., The microbiology of butyrate formation in the human colon. FEMS
Microbiol Lett, 2002. 217(2): p. 133-9.

14.

den Besten, G., et al., The role of short-chain fatty acids in the interplay between diet, gut
microbiota, and host energy metabolism. Journal of Lipid Research, 2013. 54(9): p. 23252340.

15.

Englyst, H.N., S.M. Kingman, and J.H. Cummings, Classification and measurement of
nutritionally important starch fractions. European journal of clinical nutrition, 1992. 46
Suppl 2: p. S33-50.

16.

Keenan, M.J., et al., Role of Resistant Starch in Improving Gut Health, Adiposity, and
Insulin Resistance. Advances in Nutrition: An International Review Journal, 2015. 6(2): p.
198-205.

17.

Tulley, R.T., et al., Comparative methodologies for measuring metabolizable energy of
various types of resistant high amylose corn starch. J Agric Food Chem, 2009. 57(18): p.
8474-9.

18.

Robertson, M.D., Dietary-resistant starch and glucose metabolism. Current Opinion in
Clinical Nutrition & Metabolic Care, 2012. 15(4): p. 362-367.

19.

Birt, D.F., et al., Resistant Starch: Promise for Improving Human Health. Advances in
Nutrition: An International Review Journal, 2013. 4(6): p. 587-601.

20.

Gibson, G.R. and M.B. Roberfroid, Dietary modulation of the human colonic microbiota:
introducing the concept of prebiotics. J Nutr, 1995. 125(6): p. 1401-12.

21.

Bird, A.R., I.L. Brown, and D.L. Topping, Starches, resistant starches, the gut microflora
and human health. Curr Issues Intest Microbiol, 2000. 1(1): p. 25-37.

68

22.

Duncan, S.H., et al., Acetate Utilization and Butyryl Coenzyme A (CoA):Acetate-CoA
Transferase in Butyrate-Producing Bacteria from the Human Large Intestine. Applied and
Environmental Microbiology, 2002. 68(10): p. 5186-5190.

23.

Duncan, S.H., P. Louis, and H.J. Flint, Lactate-Utilizing Bacteria, Isolated from Human
Feces, That Produce Butyrate as a Major Fermentation Product. Applied and
Environmental Microbiology, 2004. 70(10): p. 5810-5817.

24.

Canfora, E.E., J.W. Jocken, and E.E. Blaak, Short-chain fatty acids in control of body
weight and insulin sensitivity. Nat Rev Endocrinol, 2015. 11(10): p. 577-591.

25.

Brown, I.L., Applications and uses of resistant starch. J AOAC Int, 2004. 87(3): p. 72732.

26.

Young, G.P. and R.K. Le Leu, Resistant starch and colorectal neoplasia. J AOAC Int,
2004. 87(3): p. 775-86.

27.

Higgins, J.A., Resistant starch and energy balance: impact on weight loss and
maintenance. Critical reviews in food science and nutrition, 2014. 54(9): p. 1158-1166.

28.

Raigond, P., R. Ezekiel, and B. Raigond, Resistant starch in food: a review. Journal of the
Science of Food and Agriculture, 2015. 95(10): p. 1968-1978.

29.

Zhou, J., et al., Dietary resistant starch upregulates total GLP-1 and PYY in a sustained
day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab, 2008.
295(5): p. E1160-6.

30.

Zhou, J., et al., Peptide YY and proglucagon mRNA expression patterns and regulation in
the gut. Obesity (Silver Spring), 2006. 14(4): p. 683-9.

31.

Keenan, M.J., et al., Effects of Resistant Starch, A Non-digestible Fermentable Fiber, on
Reducing Body Fat. Obesity, 2006. 14(9): p. 1523-1534.

32.

Shen, L., et al., Dietary-resistant starch improves maternal glycemic control in GotoKakizaki rat. Mol Nutr Food Res, 2011. 55(10): p. 1499-508.

69

33.

Robertson, M.D., et al., Insulin-Sensitizing Effects on Muscle and Adipose Tissue after
Dietary Fiber Intake in Men and Women with Metabolic Syndrome. The Journal of Clinical
Endocrinology & Metabolism, 2012. 97(9): p. 3326-3332.

34.

Robertson, M.D., et al., Prior short-term consumption of resistant starch enhances
postprandial insulin sensitivity in healthy subjects. Diabetologia, 2003. 46(5): p. 659-65.

35.

Bodinham, C.L., G.S. Frost, and M.D. Robertson, Acute ingestion of resistant starch
reduces food intake in healthy adults. Br J Nutr, 2010. 103(6): p. 917-22.

36.

Murphy, M.M., J.S. Douglass, and A. Birkett, Resistant Starch Intakes in the United States.
Journal of the American Dietetic Association. 108(1): p. 67-78.

37.

Sekirov, I., et al., Gut Microbiota in Health and Disease. Physiological Reviews, 2010.
90(3): p. 859-904.

38.

Mandar, R. and M. Mikelsaar, Transmission of mother's microflora to the newborn at birth.
Biol Neonate, 1996. 69(1): p. 30-5.

39.

Eckburg, P.B., et al., Diversity of the human intestinal microbial flora. Science, 2005.
308(5728): p. 1635-8.

40.

Martínez, I., et al., Resistant Starches Types 2 and 4 Have Differential Effects on the
Composition of the Fecal Microbiota in Human Subjects. PLoS ONE, 2010. 5(11): p.
e15046.

41.

Tannock, G.W., The search for disease-associated compositional shifts in bowel bacterial
communities of humans. Trends Microbiol, 2008. 16(10): p. 488-95.

42.

Flint, H.J., et al., Interactions and competition within the microbial community of the
human colon: links between diet and health. Environ Microbiol, 2007. 9(5): p. 1101-11.

43.

Vangay, P., et al., Antibiotics, Pediatric Dysbiosis, and Disease. Cell Host & Microbe.
17(5): p. 553-564.

70

44.

Qin, J., et al., A metagenome-wide association study of gut microbiota in type 2 diabetes.
Nature, 2012. 490(7418): p. 55-60.

45.

Ley, R.E., D.A. Peterson, and J.I. Gordon, Ecological and evolutionary forces shaping
microbial diversity in the human intestine. Cell, 2006. 124(4): p. 837-48.

46.

Louis, P., et al., Understanding the effects of diet on bacterial metabolism in the large
intestine. J Appl Microbiol, 2007. 102(5): p. 1197-208.

47.

Kleessen, B., et al., Feeding resistant starch affects fecal and cecal microflora and shortchain fatty acids in rats. J Anim Sci, 1997. 75(9): p. 2453-62.

48.

Wang, X., et al., Manipulation of colonic bacteria and volatile fatty acid production by
dietary high amylose maize (amylomaize) starch granules. J Appl Microbiol, 2002. 93(3):
p. 390-7.

49.

Lesmes, U., et al., Effects of resistant starch type III polymorphs on human colon
microbiota and short chain fatty acids in human gut models. J Agric Food Chem, 2008.
56(13): p. 5415-21.

50.

Panda, S., et al., Short-Term Effect of Antibiotics on Human Gut Microbiota. PLoS ONE,
2014. 9(4): p. e95476.

51.

Cani, P.D., et al., Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced
Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice. Diabetes, 2008.
57(6): p. 1470-1481.

52.

Robertson, M.D., et al., Insulin-sensitizing effects of dietary resistant starch and effects on
skeletal muscle and adipose tissue metabolism. Am J Clin Nutr, 2005. 82(3): p. 559-67.

53.

Nathan, D.M., Diabetes: Advances in diagnosis and treatment. JAMA, 2015. 314(10): p.
1052-1062.

54.

De Vadder, F., et al., Microbiota-generated metabolites promote metabolic benefits via
gut-brain neural circuits. Cell, 2014. 156(1-2): p. 84-96.

71

55.

Mithieux, G., Nutrient control of energy homeostasis via gut-brain neural circuits.
Neuroendocrinology, 2014. 100(2-3): p. 89-94.

56.

Rajas, F., et al., The glucose-6 phosphatase gene is expressed in human and rat small
intestine: regulation of expression in fasted and diabetic rats. Gastroenterology, 1999.
117(1): p. 132-9.

57.

Marchesi, J.R., Human distal gut microbiome. Environmental Microbiology, 2011. 13(12):
p. 3088-3102.

58.

Zhang, D., Y. Huang, and D. Ye, Intestinal dysbiosis: An emerging cause of pregnancy
complications? Medical Hypotheses, 2015. 84(3): p. 223-226.

59.

Anhê, F., et al., Gut Microbiota Dysbiosis in Obesity-Linked Metabolic Diseases and
Prebiotic Potential of Polyphenol-Rich Extracts. Current Obesity Reports, 2015: p. 1-12.

60.

Kopecky, J., et al., The Effect of Antibiotics on Associated Bacterial Community of Stored
Product Mites. PLoS ONE, 2014. 9(11): p. e112919.

61.

Membrez, M., et al., Gut microbiota modulation with norfloxacin and ampicillin enhances
glucose tolerance in mice. FASEB J, 2008. 22(7): p. 2416-26.

62.

Manichanh, C., et al., Reshaping the gut microbiome with bacterial transplantation and
antibiotic intake. Genome Res, 2010. 20(10): p. 1411-9.

63.

Bindels, L.B., et al., Towards a more comprehensive concept for prebiotics. Nat Rev
Gastroenterol Hepatol, 2015. 12(5): p. 303-10.

64.

Walker, A.W., et al., Dominant and diet-responsive groups of bacteria within the human
colonic microbiota. The ISME journal, 2011. 5(2): p. 220-230.

65.

Reeves, P.G., F.H. Nielsen, and G.C. Fahey, Jr., AIN-93 purified diets for laboratory
rodents: final report of the American Institute of Nutrition ad hoc writing committee on the
reformulation of the AIN-76A rodent diet. J Nutr, 1993. 123(11): p. 1939-51.

72

66.

Charrier, J.A., et al., High fat diet partially attenuates fermentation responses in rats fed
resistant starch from high-amylose maize. Obesity, 2013. 21(11): p. 2350-2355.

67.

Haarman, M. and J. Knol, Quantitative real-time PCR analysis of fecal Lactobacillus
species in infants receiving a prebiotic infant formula. Appl Environ Microbiol, 2006.
72(4): p. 2359-65.

68.

Wise, M.G. and G.R. Siragusa, Quantitative analysis of the intestinal bacterial community
in one- to three-week-old commercially reared broiler chickens fed conventional or
antibiotic-free vegetable-based diets. J Appl Microbiol, 2007. 102(4): p. 1138-49.

69.

Matsuki, T., et al., Development of 16S rRNA-gene-targeted group-specific primers for the
detection and identification of predominant bacteria in human feces. Appl Environ
Microbiol, 2002. 68(11): p. 5445-51.

70.

Bartosch, S., et al., Microbiological effects of consuming a synbiotic containing
Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons,
determined by real-time polymerase chain reaction and counting of viable bacteria. Clin
Infect Dis, 2005. 40(1): p. 28-37.

71.

Belenguer, A., et al., Two routes of metabolic cross-feeding between Bifidobacterium
adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ
Microbiol, 2006. 72(5): p. 3593-9.

72.

Matsuda, K., et al., Establishment of an analytical system for the human fecal microbiota,
based on reverse transcription-quantitative PCR targeting of multicopy rRNA molecules.
Appl Environ Microbiol, 2009. 75(7): p. 1961-9.

73.

Courtney, C.L., Cecal torsion in rodents associated with chronic administration of
clinafloxacin. Toxicol Pathol, 2000. 28(5): p. 643-8.

74.

Yu, Y., et al., Combined contributions of over-secreted glucagon-like peptide 1 and
suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicology
and Applied Pharmacology, 2013. 266(3): p. 375-384.

75.

Wichmann, A., et al., Microbial modulation of energy availability in the colon regulates
intestinal transit. Cell Host Microbe, 2013. 14(5): p. 582-90.
73

76.

Hwang, I., et al., Alteration of gut microbiota by vancomycin and bacitracin improves
insulin resistance via glucagon-like peptide 1 in diet-induced obesity. The FASEB Journal,
2015. 29(6): p. 2397-2411.

77.

Rao, S.S., et al., Identification and evaluation of a novel peptide binding to the cell surface
of Staphylococcus aureus. Microbiol Res, 2013. 168(2): p. 106-12.

78.

Scribner, K.B., et al., Long-term effects of dietary glycemic index on adiposity, energy
metabolism, and physical activity in mice. Vol. 295. 2008. E1126-E1131.

79.

Keenan, M.J., et al., Effects of resistant starch, a non-digestible fermentable fiber, on
reducing body fat. Obesity (Silver Spring), 2006. 14(9): p. 1523-34.

80.

Drucker, D.J., Biological actions and therapeutic potential of the glucagon-like peptides.
Gastroenterology, 2002. 122(2): p. 531-44.

81.

Bodinham, C.L., et al., Efficacy of increased resistant starch consumption in human type
2 diabetes. Endocrine Connections, 2014. 3(2): p. 75-84.

82.

Yu, Z. and T. Jin, New insights into the role of cAMP in the production and function of the
incretin hormone glucagon-like peptide-1 (GLP-1). Cell Signal, 2010. 22(1): p. 1-8.

83.

Shen, L., et al., Dietary Resistant Starch Increases Hypothalamic POMC Expression in
Rats. Obesity, 2009. 17(1): p. 40-45.

84.

Raben, A., et al., Resistant starch: the effect on postprandial glycemia, hormonal response,
and satiety. Am J Clin Nutr, 1994. 60(4): p. 544-51.

85.

Bodinham, C.L., et al., Dietary fibre improves first-phase insulin secretion in overweight
individuals. PLoS One, 2012. 7(7): p. e40834.

86.

Willis, H.J., et al., Greater satiety response with resistant starch and corn bran in human
subjects. Nutr Res, 2009. 29(2): p. 100-5.

74

87.

Mithieux, G., A novel function of intestinal gluconeogenesis: Central signaling in glucose
and energy homeostasis. Nutrition, 2009. 25(9): p. 881-884.

88.

Mithieux, G., et al., Portal sensing of intestinal gluconeogenesis is a mechanistic link in
the diminution of food intake induced by diet protein. Cell Metabolism, 2005. 2(5): p. 321329.

89.

Duraffourd, C., et al., Mu-Opioid Receptors and Dietary Protein Stimulate a Gut-Brain
Neural Circuitry Limiting Food Intake. Cell, 2012. 150(2): p. 377-388.

90.

Pillot, B., et al., Protein Feeding Promotes Redistribution of Endogenous Glucose
Production to the Kidney and Potentiates Its Suppression by Insulin. Endocrinology, 2009.
150(2): p. 616-624.

91.

Troy, S., et al., Intestinal Gluconeogenesis Is a Key Factor for Early Metabolic Changes
after Gastric Bypass but Not after Gastric Lap-Band in Mice. Cell Metabolism, 2008. 8(3):
p. 201-211.

92.

Jitrapakdee, S., et al., Structure, Mechanism and Regulation of Pyruvate Carboxylase. The
Biochemical journal, 2008. 413(3): p. 369-387.

93.

Mithieux, G., F. Rajas, and A. Gautier-Stein, A Novel Role for Glucose 6-Phosphatase in
the Small Intestine in the Control of Glucose Homeostasis. Journal of Biological
Chemistry, 2004. 279(43): p. 44231-44234.

94.

Englyst, H.N., et al., Measurement of resistant starch in vitro and in vivo. Br J Nutr, 1996.
75(5): p. 749-55.

95.

Portha, B., et al., The GK Rat: A Prototype for the Study of Non-overweight Type 2
Diabetes, in Animal Models in Diabetes Research, H.-G. Joost, H. Al-Hasani, and A.
Schürmann, Editors. 2012, Humana Press. p. 125-159.

96.

Nauck, M.A., et al., Effects of glucagon-like peptide 1 on counterregulatory hormone
responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped
hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab, 2002.
87(3): p. 1239-46.

75

97.

Tolhurst, G., et al., Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via
the G-protein-coupled receptor FFAR2. Diabetes, 2012. 61(2): p. 364-71.

98.

Higgins, J.A., Resistant starch: metabolic effects and potential health benefits. J AOAC
Int, 2004. 87(3): p. 761-8.

99.

Pawlak, D.B., et al., High Glycemic Index Starch Promotes Hypersecretion of Insulin and
Higher Body Fat in Rats without Affecting Insulin Sensitivity. The Journal of Nutrition,
2001. 131(1): p. 99-104.

100.

Bach Knudsen, K.E., Microbial Degradation of Whole-Grain Complex Carbohydrates and
Impact on Short-Chain Fatty Acids and Health. Advances in Nutrition: An International
Review Journal, 2015. 6(2): p. 206-213.

101.

Sun, D., et al., Duodenal–Jejunal Bypass Surgery Up-Regulates the Expression of the
Hepatic Insulin Signaling Proteins and the Key Regulatory Enzymes of Intestinal
Gluconeogenesis in Diabetic Goto–Kakizaki Rats. Obesity Surgery, 2013. 23(11): p. 17341742.

76

VITA
Diana Carvajal-Aldaz was born in 1985 in Quito, Ecuador. She is pursuing her Doctorate
of Philosophy in the Molecular Human Nutrition concentration in the School of Nutrition and Food
Sciences at Louisiana State University, Baton Rouge. She received her Bachelor of Food Science
degree from Zamorano University, Valle del Yeguare, Honduras, in the year 2007. She worked as
production manager in La Tablita Group CIA. LTDA., Quito, Ecuador from July 2008 to April
2010. After that she worked as a Graduate Research Assistant in the Department of Food Science
at Louisiana State University, Baton Rouge, Louisiana under the supervision of Dr. Jack N. Losso,
from August 2010 and obtained her Master’s degree in December 2012. She is an accredited
member of the Institute of Food Science (IFT) and the American Chemical Society (ACS).

77

